WO2011069934A1 - 2-amino-5, 5-difluoro-5, 6-dihydro-4h-oxazines as bace 1 and/or bace 2 inhibitors - Google Patents

2-amino-5, 5-difluoro-5, 6-dihydro-4h-oxazines as bace 1 and/or bace 2 inhibitors Download PDF

Info

Publication number
WO2011069934A1
WO2011069934A1 PCT/EP2010/068912 EP2010068912W WO2011069934A1 WO 2011069934 A1 WO2011069934 A1 WO 2011069934A1 EP 2010068912 W EP2010068912 W EP 2010068912W WO 2011069934 A1 WO2011069934 A1 WO 2011069934A1
Authority
WO
WIPO (PCT)
Prior art keywords
difluoro
amino
dihydro
methyl
oxazin
Prior art date
Application number
PCT/EP2010/068912
Other languages
English (en)
French (fr)
Inventor
David Banner
Wolfgang Guba
Hans Hilpert
Harald Mauser
Alexander V. Mayweg
Robert Narquizian
Emmanuel Pinard
Eoin Power
Mark Rogers-Evans
Thomas Woltering
Wolfgang Wostl
Original Assignee
F. Hoffmann-La Roche Ag
Siena Biotech S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43585547&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2011069934(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to UAA201208098A priority Critical patent/UA103272C2/uk
Priority to SG2012042560A priority patent/SG181610A1/en
Priority to NZ599008A priority patent/NZ599008A/xx
Priority to BR112012013175A priority patent/BR112012013175A2/pt
Priority to MX2012006493A priority patent/MX2012006493A/es
Priority to RU2012126989/04A priority patent/RU2515221C2/ru
Priority to IN3043DEN2012 priority patent/IN2012DN03043A/en
Application filed by F. Hoffmann-La Roche Ag, Siena Biotech S.P.A. filed Critical F. Hoffmann-La Roche Ag
Priority to MA34922A priority patent/MA34779B1/fr
Priority to KR1020127017919A priority patent/KR101506773B1/ko
Priority to EP10785437A priority patent/EP2509965A1/en
Priority to CN2010800561519A priority patent/CN102712609A/zh
Priority to CA2776727A priority patent/CA2776727C/en
Priority to JP2012542481A priority patent/JP5584778B2/ja
Priority to AU2010330031A priority patent/AU2010330031B2/en
Publication of WO2011069934A1 publication Critical patent/WO2011069934A1/en
Priority to IL219107A priority patent/IL219107A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/06—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
    • C07D265/08—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention is concerned with 2-Amino-5,5-difluoro-5,6-dihydro-4H- [l,3]oxazin-4-yl)-phenyl]-amide derivatives having BACE1 and/or BACE2 inhibitory properties, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances.
  • the present invention relates to a compounds of formula I,
  • the present compounds have Asp2 ( ⁇ -secretase, BACE1 or Memapsin-2) inhibitory activity and may therefore be used in the therapeutic and/or prophylactic treatment of diseases and disorders characterized by elevated ⁇ -amyloid levels and/or ⁇ -amyloid oligomers and/or ⁇ -amyloid plaques and further deposits, particularly Alzheimer's disease. And/or the present compounds have BACE2 inhibitory activity and can therefore be used in the therapeutic and/or prophylactic treatment of diseases and disorders such as type 2 diabetes and other metabolic disorders.
  • AD Alzheimer's disease
  • Its clinical symptoms are impairment of memory, cognition, temporal and local orientation, judgment and reasoning but also severe emotional disturbances.
  • AD has become a major health problem in all societies with high life expectancies and also a significant economic burden for their health systems.
  • AD is characterized by 2 major pathologies in the central nervous system (CNS), the occurrence of amyloid plaques and neurofibrillar tangles (Hardy et al, The amyloid hypothesis
  • APP ⁇ -amyloid precursor protein
  • proteolytic cleavage steps Several forms of APP have been identified of which the most abundant are proteins of 695, 751 and 770 amino acids length. They all arise from a single gene through differential splicing.
  • the ⁇ -peptides are derived from the same domain of the APP but differ at their N- and C-termini, the main species are of 40 and 42 amino-acid length.
  • ⁇ -peptides are the essential molecules in the pathogenesis of AD: 1) amyloid plaques formed of ⁇ -peptides are invariably part of the AD pathology; 2) ⁇ - peptides are toxic for neurons; 3) in Familial Alzheimer's Disease (FAD) the mutations in the disease genes APP, PSN1, PSN2 lead to increased levels of ⁇ -peptides and early brain amyloidosis; 4) transgenic mice which express such FAD genes develop a pathology which bears many resemblances to the human disease.
  • ⁇ -peptides are produced from APP through the sequential action of 2 proteolytic enzymes termed ⁇ - and ⁇ -secretase.
  • ⁇ -Secretase cleaves first in the extracellular domain of APP approximately 28 amino acids outside of the trans-membrane domain (TM) to produce a C-terminal fragment of APP containing the TM- and the cytoplasmatic domain (CTFP).
  • CTF ⁇ is the substrate for ⁇ -secretase which cleaves at several adjacent positions within the TM to produce the ⁇ peptides and the cytoplasmic fragment.
  • the ⁇ -secretase is a complex of at least 4 different proteins, its catalytic subunit is very likely a presenilin protein (PSEN1, PSEN2).
  • the ⁇ -secretase (BACE1, Asp2; BACE stands for ⁇ -site APP-cleaving enzyme) is an aspartyl protease which is anchored into the membrane by a transmembrane domain (Vassar et al, Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE, Science. 1999 Oct 22; 286(5440): 735). It is expressed in many tissues of the human organism but its level is especially high in the CNS.
  • mice which have been genetically engineered to express the human APP gene and which form extensive amyloid plaques and Alzheimer's disease like pathologies during aging fail to do so when ⁇ -secretase activity is reduced by genetic ablation of one of the BACE1 alleles (McConlogue et al, Partial reduction of BACE 1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP Transgenic Mice. J Biol Chem. 2007 Sep 7;282(36):26326). It is thus presumed that inhibitors of BACEl activity can be useful agents for therapeutic intervention in Alzheimer's Disease (AD).
  • AD Alzheimer's Disease
  • Type 2 diabetes is caused by insulin resistance and inadequate insulin secretion from pancreatic ⁇ -cells leading to poor blood-glucose control and hyperglycemia (M Prentki & CJ Nolan, "Islet beta-cell failure in type 2 diabetes.” J. Clin. Investig. 2006, 116(7), 1802-1812).
  • Patients with T2D have an increased risk of microvascular and macrovascular disease and a range of related complications including diabetic nephropathy, retinopathy and cardiovascular disease.
  • Tmem27 has been identified as a protein promoting beta-cell proliferation (P Akpinar, S Kuwajima, J Krutzfeldt, M Stoffel, "Tmem27: A cleaved and shed plasma membrane protein that stimulates pancreatic ⁇ cell proliferation", Cell Metab. 2005, 2, 385-397) and insulin secretion (K Fukui, Q Yang, Y Cao, N Takahashi et al, "The HNF-1 target Collectrin controls insulin exocytosis by SNARE complex formation", Cell Metab. 2005, 2, 373-384).
  • Tmem27 is a 42 kDa membrane glycoprotein which is constitutively shed from the surface of ⁇ -cells, resulting from a degradation of the full-length cellular Tmem27.
  • Overexpression of Tmem27 in a transgenic mouse increases ⁇ -cell mass and improves glucose tolerance in a diet-induced obesity DIO model of diabetes.
  • siRNA knockout of Tmem27 in a rodent ⁇ -cell proliferation assay reduces the proliferation rate, indicating a role for Tmem27 in control of ⁇ -cell mass.
  • BACE2 inhibitors In the same proliferation assay, BACE2 inhibitors also increase proliferation. However, BACE2 inhibition combined with Tmem27 siRNA knockdown results in low proliferation rates. Therefore, it is concluded that BACE2 is the protease responsible for the degradation of Tmem27. Furthermore, in vitro, BACE2 cleaves a peptide based on the sequence of Tmem27. The closely related protease BACEl does not cleave this peptide and selective inhibition of BACEl alone does not enhance proliferation of ⁇ -cells.
  • BACE2 The close homolog BACE2 is a membrane-bound aspartyl protease and is co-localized with Tmem27 in human pancreatic ⁇ -cells (G Finzi, F Franzi, C Placidi, F Acquati et al, "BACE2 is stored in secretory granules of mouse and rat pancreatic beta cells", Ultrastruct Pathol. 2008, 32(6), 246-251). It is also known to be capable of degrading APP (I Hussain, D Powell, D Howlett, G Chapman et al, "ASP1 (BACE2) cleaves the amyloid precursor protein at the ⁇ -secretase site" Mol Cell Neurosci.
  • IL-1R2 P Kuhn, E Marjaux, A Imhof, B De Strooper et al, "Regulated intramembrane proteolysis of the interleukin-1 receptor II by alpha-, beta-, and gamma-secretase" J. Biol. Chem. 2007, 282(16), 11982-11995) and ACE2.
  • the capability to degrade ACE2 indicates a possible role of BACE2 in the control of hypertension.
  • BACE2 Inhibition of BACE2 is therefore proposed as a treatment for T2D with the potential to preserve and restore ⁇ -cell mass and stimulate insulin secretion in pre-diabetic and diabetic patients. It is therefore an object of the present invention to provide selective BACE2 inhibitors. Such compounds are useful as therapeutically active substances, particularly in the treatment and/or prevention of diseases which are associated with the inhibition of BACE2.
  • ⁇ -amyloid peptides in, on or around neurological tissue are inhibited by the present compounds, i.e. inhibition of the ⁇ -production from APP or an APP fragment.
  • WO 2007/049 532 and WO 2008/133 274 describe amino dihydrothiazine derivatives as BACE1 inhibitors, and WO 2008/133 273 describes pharmaceutical compositions of BACE1 inhibitors.
  • Inhibitors of BACE1 and/or BACE2 can in addition be used to treat the following diseases: IBM (inclusion body myositis) (Vattemi G. et al, Lancet. 2001 Dec 8;358(9297): 1962-4), Down's Syndrome (Barbiero L. et al, Exp Neurol. 2003 Aug;182(2):335-45), Wilson's Disease (Sugimoto I. et al, J Biol Chem. 2007 Nov 30;282(48):34896-903), Whipple's disease (Desnues B. et al, Clin Vaccine Immunol.
  • Objects of the present invention are novel compounds of formula I, their manufacture, medicaments based on a compound in accordance with the invention and their production as well as the use of compounds of formula I in the control or prevention of illnesses such as Alzheimer's disease and type 2 diabetes. Furthermore the use of compounds of formula I in the treatment of amyotrophic lateral sclerosis (ALS), arterial thrombosis, autoimmune/inflammatory diseases, cancer such as breast cancer, cardiovascular diseases such as myocardial infarction and stroke, dermatomyositis, Down's Syndrome, gastrointestinal diseases, Glioblastoma multiforme, Graves Disease, Huntington's Disease, inclusion body myositis (IBM), inflammatory reactions, Kaposi Sarcoma, Kostmann Disease, lupus erythematosus, macrophagic myofasciitis, juvenile idiopathic arthritis, granulomatous arthritis, malignant melanoma, multiple mieloma, rheumatoid arthritis, S
  • Object of the present invention is a compound of formula I and their pharmaceutically acceptable salts thereof, the preparation of the above mentioned compounds, medicaments containing them and their manufacture as well as the use of the above mentioned compounds in the therapeutic and/or prophylactic treatment of diseases and disorders which are associated with inhibition of BACE1 and/or BACE2 activity, such as Alzheimer's disease and type 2 diabetes. Furthermore, the formation, or formation and deposition, of ⁇ -amyloid plaques in, on or around neurological tissue (e.g., the brain) are inhibited by the present compounds by inhibiting the ⁇ production from APP or an APP fragment.
  • lower alkyl stands for a hydrocarbon radical which may be linear or branched, with single or multiple branching, whereby the alkyl group in general comprises 1 to 6 carbon atoms, for example, methyl (Me), ethyl (Et), propyl, isopropyl (i-propyl), n-butyl, i-butyl (iso-butyl), 2-butyl (sec-butyl), t-butyl (tert-butyl) and the like.
  • Preferred alkyl groups are groups with 1 to 4 carbon atoms. Most preferred is methyl.
  • cyano-lower alkyl refers to lower alkyl as defined herewithin, which is substituted by one or multiple cyano, preferably 1-5 cyano, more preferably 1 cyano. Examples are cyano-methyl and the like.
  • halo gen- lower alkyl refers to lower alkyl as defined herewithin, which is substituted by one or multiple halogen, preferably 1-5 halogen, more preferably 1-3 halogen, most preferably 1 halogen or 3 halogen. Examples are trifluoromethyl, chloromethyl, fluoromethyl and the like.
  • cycloalkyl-lower alkyl refers to lower alkyl as defined herewithin, which is substituted by one cycloalkyl as defined herein. Examples are cyclopropylmethyl, cyclopropylethyl and the like.
  • lower alkoxy-lower alkyl refers to lower alkyl, which is substituted by one or multiple lower alkoxy as defined herewithin. Examples are MeO-Me, lMeO-Et, 2MeO-Et, lMeO-2EtO-propyl and the like.
  • lower alkyl substituted by stands for a lower alkyl as defined herein, which is substituted by one or multiple substituents, preferably 1-5 substituents with a substituent individually selected from the group as specified for each specific "lower alkyl substituted by”, e.g. cyano, halogen, hydroxy and lower alkoxy.
  • lower alkenyl denotes a monovalent linear or branched hydrocarbon group of 2 to 7 carbon atoms, in particular 2 to 4 carbon atoms, with at least one double bond.
  • alkenyl include ethenyl, propenyl, prop-2-enyl, isopropenyl, n-butenyl, i-butenyl, and t-butenyl. Particular is ethenyl.
  • lower alkenyl substituted by stands for a lower alkenyl as defined herein, which is substituted by one or multiple substituents, preferably 1-4 substituents with a substituent individually selected from the group as specified for each specific "lower alkenyl substituted by”, e.g. cyano, cyano-lower alkyl, halogen, halogen-lower alkoxy, halogen-lower alkyl, heteroaryl, lower alkoxy, lower alkoxy-lower alkyl and lower alkyl.
  • cycloalkyl-lower alkenyl refers to lower alkenyl as defined herewithin, which is substituted by one cycloalkyl as defined herein. Examples are cyclopropyl-ethenyl, cyclopropyl- propenyl and the like.
  • lower alkynyl denotes a monovalent linear or branched saturated hydrocarbon group of 2 to 7 carbon atoms, in particular from 2 to 4 carbon atoms, and comprising one, two or three triple bonds. Examples of alkynyl include ethynyl, propynyl, prop-2-ynyl, isopropynyl, n- butynyl and iso-butynyl.
  • cycloalkyl-lower alkynyl refers to lower alkynyl as defined herewithin, which is substituted by one cycloalkyl as defined herein. Examples are cyclopropyl-ethynyl, cyclopropyl- propynyl and the like.
  • cyano alone or in combination with other groups, refers to N ⁇ C- (NC-).
  • nitro alone or in combination with other groups, refers to -N0 2 .
  • hydroxy alone or in combination with other groups, refers to -OH.
  • halogen alone or in combination with other groups, denotes chloro (CI), iodo (I), fluoro (F) and bromo (Br). Preferred "halogen” is CI and F.
  • aryl refers to an aromatic carbocyclic group comprising 6 to 14, preferably 6 to 10, carbon atoms and having at least one aromatic ring or multiple condensed rings in which at least one ring is aromatic.
  • aryl include benzyl, biphenyl, indanyl, naphthyl, phenyl (Ph) and the like.
  • Preferred “aryl” is phenyl.
  • aryl substituted by refers to an aryl which is substituted by one or multiple substituents, preferably 1-4 substituents, whereby substitution at each ring atom individually is possible, with a substituent individually selected from the group as specified for each specific "aryl substituted by", e.g. from cyano, cyano-lower alkyl, halogen, halogen-lower alkoxy, halogen-lower alkyl, lower alkoxy, lower alkoxy-lower alkyl and lower alkyl. Examples are halogen-aryl, chloro-phenyl. fiuoro-phenyl, lower alkyl-aryl, methyl-phenyl, lower alkoxy-aryl, methoxy-phenyl and the like.
  • heteroaryl refers to an aromatic carbocyclic group of having a single 4 to 8 membered ring or multiple condensed rings comprising 6 to 14, more preferably 6 to 10, ring atoms and containing 1, 2 or 3 heteroatoms individually selected from N, O and S, in particular N and O, in which group at least one heterocyclic ring is aromatic.
  • heteroaryl examples include benzofuryl, benzoimidazolyl, benzooxazinyl, benzo thiazinyl, benzo thiazolyl, benzo thienyl, benzo triazolyl, furyl, imidazolyl, indazolyl, indolyl, isoquinolinyl, isothiazolyl, isoxazolyl, oxazolyl, pyrazinyl, pyrazolyl (pyrazyl), pyrazolo[l,5-a]pyridinyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, quinolinyl, tetrazolyl, thiazolyl, thienyl, triazolyl and the like.
  • heteroaryl substituted by refers to a heteroaryl which is substituted by one or multiple substituents, preferably 1-4 substituents, whereby substitution at each ring atom individually is possible, the substituent is individually selected from the group as specified for each specific "heteroaryl substituted by", i.e. for example from cyano, cyano-lower alkyl, halogen, halogen-lower alkoxy, halogen-lower alkyl, lower alkoxy, lower alkoxy-lower alkyl and lower alkyl.
  • heteroaryl substituted by are heteroaryl substituted by 1-2 substituents individually selected from cyano, halogen, halogen- lower alkoxy, halogen-lower alkyl and lower alkyl. More preferred are (2,2,2-Trifluoroethoxy)- pyridine-2-yl, 3,5-Dichloro-pyridine-2-yl, 3,5-Difluoro-pyridine-2-yl, 3-Chloro-5-fluoro- pyridine-2-yl, 3-Chloro-5-trifluoromethyl-pyridine-2-yl, 3-Chloro-pyridine-2-yl, 3-Fluoro- pyridine-2-yl, 3-Trifluoromethyl-pyridine-2-yl, 4-Chloro-l-methyl-lH-pyrazol-3-yl, 5-Chloro-3- fluoro-pyridine-2-yl, 5-Chloro-3-methyl-pyridine-2-yl, 5-Chloro-pyridine-2-yl, 5-Chloro-pyr
  • lower alkoxy stands for an -O-lower alkyl radical which may be linear or branched, with single or multiple branching, whereby the alkyl group in general comprises 1 to 6 carbon atoms, for example, methoxy (OMe, MeO), ethoxy (OEt), propoxy, isopropoxy (i-propoxy), n-butoxy, i-butoxy (iso-butoxy), 2-butoxy (sec-butoxy), t-butoxy (tert-butoxy), isopentyloxy (i-pentyloxy) and the like.
  • Preferred "lower alkoxy” are groups with 1 to 4 carbon atoms. Most preferred is methoxy.
  • halo gen- lower alkoxy refers to lower alkoxy as defined herewithin, which is substituted by one or multiple halogens.
  • Preferred "halo gen- lower alkoxy” are fluoro-lower alkoxy, fluoro-ethoxy and halogen-ethoxy, most preferred is 2,2,2-trifluoro-ethoxy.
  • cycloalkyl-lower alkoxy refers to lower alkoxy as defined herewithin, which is substituted by one cycloalkyl as defined herein. Examples are cyclopropyl-ethoxy, cyclopropyl-methoxy and the like.
  • cycloalkyl denotes a monovalent saturated monocyclic or bicyclic hydrocarbon group of 3 to 10 ring carbon atoms, particularly a monovalent saturated monocyclic hydrocarbon group of 3 to 8 ring carbon atoms.
  • Bicyclic means consisting of two saturated carbocycles having two carbon atoms in common, i.e. the bridge separating the two rings is either a single bond or a chain of one or two carbon atoms.
  • Particular cycloalkyl groups are monocyclic. Examples for monocyclic cycloalkyl are cyclopropyl, cyclobutanyl, cyclopentyl, cyclohexyl or cycloheptyl.
  • bicyclic cycloalkyl examples are bicyclo[2.2.1]heptanyl, bicyclo[2.2.2]octanyl or adamantanyl. Particular is cyclopropyl.
  • cycloalkyl substituted by alone or in combination with other groups, refers to a cycloalkyl as defined herein, which is substituted by one or multiple substituents, preferably 1-4 substituents, whereby substitution at each ring atom individually is possible, the substituent is individually selected from the group as specified for each specific "cycloalkyl substituted by", i.e. for example from cyano, cyano-lower alkyl, halogen, halogen-lower alkoxy, halogen-lower alkyl, lower alkoxy, lower alkoxy-lower alkyl and lower alkyl.
  • salts refers to salts that are suitable for use in contact with the tissues of humans and animals.
  • suitable salts with inorganic and organic acids are, but are not limited to acetic acid, citric acid, formic acid, fumaric acid, hydrochloric acid, lactic acid, maleic acid, malic acid, methane-sulfonic acid, nitric acid, phosphoric acid, p-toluenesulphonic acid, succinic acid, sulfuric acid, sulphuric acid, tartaric acid, trifluoro acetic acid and the like.
  • Preferred are formic acid, trifluoro acetic acid and hydrochloric acid. Most preferred is hydrochloric acid.
  • pharmaceutically acceptable carrier and “pharmaceutically acceptable auxiliary substance” refer to carriers and auxiliary substances such as diluents or excipients that are compatible with the other ingredients of the formulation.
  • composition encompasses a product comprising specified ingredients in pre-determined amounts or proportions, as well as any product that results, directly or indirectly, from combining specified ingredients in specified amounts.
  • a product comprising one or more active ingredients, and an optional carrier comprising inert ingredients, as well as any product that results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients.
  • IC 50 half maximal inhibitory concentration
  • IC 50 values can be converted logarithmically to pIC 5 o values (-log IC 50 ), in which higher values indicate exponentially greater potency.
  • the IC 50 value is not an absolute value but depends on experimental conditions e.g. concentrations employed.
  • the IC 50 value can be converted to an absolute inhibition constant (Ki) using the Cheng-Prusoff equation (Biochem. Pharmacol. (1973) 22:3099).
  • Ki absolute inhibition constant
  • Ki values can be converted logarithmically to pKi values (-log Ki), in which higher values indicate exponentially greater potency.
  • “Therapeutically effective amount” means an amount of a compound that, when administered to a subject for treating a disease state, is sufficient to effect such treatment for the disease state.
  • the “therapeutically effective amount” will vary depending on the compound, disease state being treated, the severity or the disease treated, the age and relative health of the subject, the route and form of administration, the judgment of the attending medical or veterinary practitioner, and other factors.
  • variable incorporates by reference the broad definition of the variable as well as preferred, more preferred and most preferred definitions, if any.
  • treating when referring to a chemical reaction means adding or mixing two or more reagents under appropriate conditions to produce the indicated and/or the desired product. It should be appreciated that the reaction which produces the indicated and/or the desired product may not necessarily result directly from the combination of two reagents which were initially added, i.e., there may be one or more intermediates which are produced in the mixture which ultimately leads to the formation of the indicated and/or the desired product.
  • the invention also provides pharmaceutical compositions, methods of using, and methods of preparing the aforementioned compounds.
  • One embodiment of the invention is a compound of formula I,
  • R is selected from the group consisting of
  • cycloalkyl substituted by 1-4 substituents individually selected from cyano, cyano- lower alkyl, halogen, halogen-lower alkoxy, halogen-lower alkyl, lower alkoxy, lower alkoxy-lower alkyl and lower alkyl,
  • R 2 is selected from the group consisting of
  • R 3 is lower alkyl
  • R 4 is selected from the group consisting of
  • R 5 is selected from the group consisting of
  • n 0, 1 or 2;
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein
  • R 1 is selected from the group consisting of
  • R 2 is selected from the group consisting of
  • R 3 is lower alkyl
  • R 4 is selected from the group consisting of
  • R 5 is selected from the group consisting of
  • n 0, 1 or 2;
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein
  • R 1 is selected from the group consisting of
  • R 2 is selected from the group consisting of
  • R 3 is lower alkyl
  • R 4 is selected from the group consisting of
  • R 5 is selected from the group consisting of
  • n 0, 1 or 2;
  • a certain embodiment of the invention relates to a compound of formula la as described herein wherein
  • R 1 is selected from the group consisting of
  • R 2 is selected from the group consisting of
  • R 3 is lower alkyl
  • R 4 is selected from the group consisting of
  • R 5 is selected from the group consisting of
  • R 3 is lower alkyl
  • R 4 is selected from the group consisting of
  • R 5 is selected from the group consisting of
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is selected from the group consisting of i) lH-pyrazolyl, optionally substituted by 1-2 substituents individually selected from cycloalkyl, halogen, halogen-lower alkyl, lower alkyl,
  • cycloalkyl optionally substituted by 1-2 substituents individually selected from halogen and halo gen- lower alkyl,
  • oxazolyl optionally substituted by 1-2 substituents individually selected from cycloalkyl, halogen-lower alkyl and lower alkyl,
  • pyrazinyl optionally substituted by 1-2 substituents individually selected from cycloalkyl-lower alkoxy, halogen, halogen-lower alkyl and lower alkyl
  • pyrazolyl optionally substituted by 1-2 substituents individually selected from halogen and lower alkyl
  • pyridinyl optionally substituted by 1-2 substituents individually selected from amido, cyano, cycloalkyl-lower alkoxy, cycloalkyl-lower alkynyl, halogen, halogen-lower alkyl, lower alkyl and halogen-lower alkoxy; and
  • xii) pyrimidinyl optionally substituted by 1-2 substituents individually selected from halogen and halo gen- lower alkyl.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is selected from the group consisting of i) pyridinyl,
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is selected from the group consisting of
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is selected from the group consisting of 5-Chloro-pyridine-2-yl, 3-Chloro-5- trifiuoromethyl-pyridine-2-yl, 3-Chloro-5-fiuoro-pyridine-2-yl, 3,5-Dichloro-pyridine-2-yl, 5- Cyano-pyridine-2-yl, 5-Chloro-3-fiuoro-pyridine-2-yl, 5-Chloro-pyridine-2-yl and 3-Chloro-5- trifiuoromethyl-pyridine-2-yl.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is lH-pyrazolyl, optionally substituted by 1-2 substituents individually selected from cycloalkyl, halogen, halogen-lower alkyl, lower alkyl.
  • R 1 is lH-pyrazolyl, in particular lH-pyrazol-3-yl and lH-pyrazol-5-yl.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is lH-pyrazolyl substituted by difluoromethyl, in particular 1- (difluoromethyl)- lH-pyrazol-3-yl.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is lH-pyrazolyl substituted by methyl, in particular 1 -methyl- lH-pyrazo 1-3 -yl and 4-methyl-lH-pyrazol-5-yl.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is lH-pyrazolyl substituted by chloro, in particular 4-chloro-lH-pyrazol-5-yl.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is lH-pyrazolyl substituted by chloro and cycloalkyl, in particular 4-chloro-3- cyclopropyl- 1 H-pyrazol-5-yl.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is lH-pyrazolyl substituted by chloro and difluoro ethyl, in particular 4- chloro- 1 -(2,2-difluoroethyl)- lH-pyrazol-3-yl.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is lH-pyrazolyl substituted by chloro and difluoromethyl, in particular 4- chloro- 1 -(difluoromethyl)- 1 H-pyrazo 1-3 -yl.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is lH-pyrazolyl substituted by chloro and trifluoro ethyl, in particular 4- chloro- 1 -(2,2,2-trif uoroethyl)- 1 H-pyrazo 1-3 -yl.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is cycloalkyl, optionally substituted by 1-2 substituents individually selected from halogen and halogen-lower alkyl.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is cycloalkyl, in particular cyclopropyl.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is cycloalkyl substituted by fluoro, in particular 2,2-difluorocycloprop-l-yl.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is cycloalkyl substituted by trifluoromethyl, in particular 1- (trifluoromethyl)cycloprop- 1 -yl.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is lower alkenyl, optionally substituted by heteroaryl.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is lower alkenyl, in particular ethenyl.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is lower alkenyl substituted by heteroaryl, in particular 1-furyl-ethenyl.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is lower alkyl, optionally substituted by 1-5 substituents individually selected from halogen and hydroxy.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is lower alkyl, in particular methyl and isopropyl.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is lower alkyl substituted by fluoro and hydroxy, in particular 2,2,2-trifluoro- 1 -hydroxy- 1 -methyl-2-ethyl.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is furyl, optionally substituted by nitro.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is furyl, in particular fur-2-yl.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is furyl substituted by nitro, in particular 5-nitro-fur-2-yl.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is isoxazolyl, optionally substituted by 1-2 lower alkyl.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is isoxazolyl, in particular isoxazol-3-yl.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is isoxazolyl substituted by lower alkyl, in particular 4-methylisoxazol-3-yl.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is oxazolyl, optionally substituted by 1-2 substituents individually selected from cycloalkyl, halogen-lower alkyl and lower alkyl.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is oxazolyl, in particular oxazol-4-yl.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is oxazolyl substituted by lower alkyl, in particular 2-ethyl-oxazol-4-yl, 5- ethyl-oxazol-4-yl, 5-isopropyl-oxazol-4-yl, 2,5-dimethyl-oxazol-4-yl and 2-methyl-oxazol-4-yl.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is oxazolyl substituted by halogen-lower alkyl, in particular 2- (chloromethyl)oxazol-4-yl and 2-(fluoromethyl)oxazol-4-yl.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is oxazolyl substituted by halogen-lower alkyl and lower alkyl, in particular 2-methyl-5 -(trifluoromethyl)oxazo 1-4-yl.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is oxazolyl substituted by cycloalkyl, in particular 5 -eye lopropyl-oxazo 1-4-yl.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is pyrazinyl, optionally substituted by 1-2 substituents individually selected from cycloalkyl-lower alkoxy, halogen, halogen-lower alkyl and lower alkyl.
  • R 1 is pyrazinyl, in particular pyrazin-2-yl.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is pyrazinyl substituted by halogen, in particular 5-chloro-pyrazin-2-yl and 3,5-dichloro-pyrazin-2-yl.
  • R 1 is pyrazinyl substituted by halogen-lower alkyl, in particular 5- trifluoromethyl-pyrazine-2-yl.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is pyrazinyl substituted by lower alkyl, in particular 5-methyl-pyrazin-2-yl.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is pyrazinyl substituted by cycloalkyl-lower alkoxy, in particular 5- (cyclopropylmethoxy)pyrazin-2-yl.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is pyrazolyl, optionally substituted by 1-2 substituents individually selected from halogen and lower alkyl.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is pyrazolyl, in particular pyrazol-3-yl.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is pyrazolyl substituted by halogen and lower alkyl, in particular 4-chloro-l- methyl- 1 H-pyrazo 1-3 -yl.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is pyridazinyl, optionally substituted by 1-2 halogen.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is pyridazinyl, in particular pyridazin-3-yl.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is pyridazinyl substituted by halogen, in particular 6-chloro-pyridazin-3-yl.
  • R 1 is pyridinyl, optionally substituted by 1-2 substituents individually selected from amido, cyano, cycloalkyl-lower alkoxy, cycloalkyl-lower alkynyl, halogen, halogen-lower alkyl, lower alkyl and halogen-lower alkoxy.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is pyridinyl, in particular pyridine-2-yl.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is pyridinyl substituted by amido, in particular 5-amido-pyridin-2-yl.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is pyridinyl substituted by cyano, in particular 5-cyano-pyridin-2-yl.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is the N-oxide of pyridinyl substituted by cyano, in particular 5-cyano- pyridin- 1 -oxide-2-yl.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is pyridinyl substituted by halogen.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is pyridinyl substituted by chloro, in particular 5-chloro-pyridin-2-yl, 3,5- dichloro-pyridin-2-yl and 3-chloro-pyridin-2-yl.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is pyridinyl substituted by fluoro, in particular 5-fluoro-pyridin-2-yl, 3,5- difluoro-pyridin-2-yl and 3-fluoro-pyridin-2-yl.
  • R 1 is pyridinyl substituted by fluoro, in particular 5-fluoro-pyridin-2-yl, 3,5- difluoro-pyridin-2-yl and 3-fluoro-pyridin-2-yl.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is pyridinyl substituted by halogen and cyano, in particular 3-chloro-5-cyano- pyridin-2-yl.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is pyridinyl substituted by halogen and lower alkyl, in particular 5-chloro-3- methyl-pyridin-2-yl.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is pyridinyl substituted by halogen-lower alkoxy.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is pyridinyl substituted by trifluoroethoxy, in particular 3-(2,2,2- trifluoroethoxy)-pyridin-2-yl and 5-(2,2,2-trifluoroethoxy)-pyridin-2-yl.
  • R 1 is pyridinyl substituted by difluoroethoxy, in particular 5-(2,2- difluoroethoxy)-pyridin-2-yl.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is pyridinyl substituted by tetrafluoropropoxy, in particular 5-(2,2,3,3- tetrafluoro-propoxy)-pyridin-2-yl.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is pyridinyl substituted by pentafluoropropoxy, in particular 5-(2,2,3,3,3- pentafluoro-propoxy)-pyridin-2-yl.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is pyridinyl substituted by difluoromethoxy, in particular 5- (difluoromethoxy)-pyridin-2-yl.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is pyridinyl substituted by fluoromethoxy, in particular 5-(fluoromethoxy)- pyridin-2-yl.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is pyridinyl substituted by cycloalkyl-lower alkoxy, in particular 6- (cyclopropylmethoxy)-pyridin-3-yl.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is pyridinyl substituted by halogen-lower alkyl, in particular 3- trifluoromethyl-pyridin-2-yl and 5-trifluoromethyl-pyridin-2-yl.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is pyrimidinyl, optionally substituted by 1-2 substituents individually selected from halogen and halogen-lower alkyl.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is pyrimidinyl, in particular pyrimidin-2-yl.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is pyrimidinyl substituted by halogen, in particular 5-chloro-pyrimidin-2-yl.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 1 is pyrimidinyl substituted by halogen-lower alkyl, in particular 5- trifluoromethyl-pyrimidin-2-yl.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein n is 1.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein n is 0.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein n is 2.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 2 is hydrogen.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 2 is halogen.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 2 is fluoro.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 2 is chloro.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 3 is lower alkyl.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 3 is methyl.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 4 is hydrogen.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 4 is lower alkyl.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 4 is methyl.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 5 is hydrogen.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 5 is lower alkyl.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, wherein R 5 is methyl.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, selected from the group consisting of 5-Chloro-pyridine-2-carboxylic acid [3-((R)-2-amino-5,5-difluoro-4-methyl-5,6-dihydro-4H- [ 1 ,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
  • a certain embodiment of the invention relates to a compound of formula I as described herein, selected from the group consisting of 5-Chloro-pyridine-2-carboxylic acid [3-((R)-2-amino-5,5-difluoro-4-methyl-5,6-dihydro-4H- [ 1 ,3]oxazin-4-yl)-4-fluoro-phenyl]-amide,
  • a certain embodiment of the invention relates to a compound of formula I as described herein, selected from the group consisting of 5-Cyano-pyridine-2-carboxylic acid [3-((R)-2- amino-5,5-difluoro-4-methyl-5,6-dihydro-4H-[l,3]oxazin-4-yl)-4-fluoro-phenyl]-amide and 5- Cyano-pyridine-2-carboxylic acid [3-((R)-2-amino-5,5-difluoro-4-methyl-5,6-dihydro-4H- [l,3]oxazin-4-yl)-4-fluoro-phenyl]-amide hydrochloride.
  • a certain embodiment of the invention relates to a process to synthesize a compound of formula I as described herein, which process comprises reacting a compound of formula II with a compound of formula III.
  • R 1 , R 2 , R 3 , R 4 , R 5 are as herein.
  • a certain embodiment of the invention relates to a compound of formula I as described herein, whenever prepared by a process as defined above.
  • a certain embodiment of the invention relates to a compound of formula I as described herein for use as therapeutically active substance.
  • a certain embodiment of the invention relates to a compound of formula I as described herein for the use as inhibitor of BACE1 and/or BACE2 activity.
  • a certain embodiment of the invention relates to a compound of formula I as described herein for the use as inhibitor of BACE1 activity.
  • a certain embodiment of the invention relates to a compound of formula I as described herein for the use as inhibitor of BACE2 activity.
  • a certain embodiment of the invention relates to a compound of formula I as described herein for the use as inhibitor of BACE1 and BACE2 activity.
  • a certain embodiment of the invention relates to a compound of formula I as described herein for the use as therapeutically active substance for the therapeutic and/or prophylactic treatment of diseases and disorders characterized by elevated ⁇ -amyloid levels and/or ⁇ -amyloid oligomers and/or ⁇ -amyloid plaques and further deposits, particularly Alzheimer's disease.
  • a certain embodiment of the invention relates to a compound of formula I as described herein for the use as therapeutically active substance for the therapeutic and/or prophylactic treatment of Alzheimer's disease.
  • a certain embodiment of the invention relates to a compound of formula I as described herein for the use as therapeutically active substance for the therapeutic and/or prophylactic treatment of diabetes, particularly type 2 diabetes.
  • a certain embodiment of the invention relates to a compound of formula I as described herein for the use as therapeutically active substance for the therapeutic and/or prophylactic treatment of amyotrophic lateral sclerosis (ALS), arterial thrombosis, autoimmune/inflammatory diseases, cancer such as breast cancer, cardiovascular diseases such as myocardial infarction and stroke, dermatomyositis, Down's Syndrome, gastrointestinal diseases, Glioblastoma multiforme, Graves Disease, Huntington's Disease, inclusion body myositis (IBM), inflammatory reactions, Kaposi Sarcoma, Kostmann Disease, lupus erythematosus, macrophagic myofasciitis, juvenile idiopathic arthritis, granulomatous arthritis, malignant melanoma, multiple mieloma, rheumatoid arthritis, Sjogren syndrome, Spinocerebellar Ataxia 1, Spinocerebellar Ataxia 7, Whipple's Disease or Wilson's Disease.
  • a certain embodiment of the invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula I as described herein and a pharmaceutically acceptable carrier and/or a pharmaceutically acceptable auxiliary substance.
  • a certain embodiment of the invention relates to the use of a compound of formula I as described herein for the manufacture of a medicament for the use in inhibition of BACEl and/or BACE2 activity.
  • a certain embodiment of the invention relates to the use of a compound of formula I as described herein for the manufacture of a medicament for the use in inhibition of BACEl activity.
  • a certain embodiment of the invention relates to the use of a compound of formula I as described herein for the manufacture of a medicament for the use in inhibition of BACE2 activity.
  • a certain embodiment of the invention relates to the use of a compound of formula I as described herein for the manufacture of a medicament for the use in inhibition of BACEl and BACE2 activity.
  • a certain embodiment of the invention relates to the use of a compound of formula I as described herein for the manufacture of a medicament for the therapeutic and/or prophylactic treatment of diseases and disorders characterized by elevated ⁇ -amyloid levels and/or ⁇ -amyloid oligomers and/or ⁇ -amyloid plaques and further deposits, particularly Alzheimer's disease.
  • a certain embodiment of the invention relates to the use of a compound of formula I as described herein for the manufacture of a medicament for the therapeutic and/or prophylactic treatment of Alzheimer's disease.
  • a certain embodiment of the invention relates to the use of a compound of formula I as described herein for the manufacture of a medicament for the therapeutic and/or prophylactic treatment of diabetes, particularly type 2 diabetes.
  • a certain embodiment of the invention relates to a compound of formula I as described herein for the use in inhibition of BACEl and/or BACE2 activity.
  • a certain embodiment of the invention relates to a compound of formula I as described herein for the use in inhibition of BACEl activity.
  • a certain embodiment of the invention relates to a compound of formula I as described herein for the use in inhibition of BACE2 activity.
  • a certain embodiment of the invention relates to a compound of formula I as described herein for the use in inhibition of BACEl and BACE2 activity.
  • a certain embodiment of the invention relates to a compound of formula I as described herein for the use in the therapeutic and/or prophylactic treatment of diseases and disorders characterized by elevated ⁇ -amyloid levels and/or ⁇ -amyloid oligomers and/or ⁇ -amyloid plaques and further deposits, particularly Alzheimer's disease.
  • a certain embodiment of the invention relates to a compound of formula I as described herein for the use in the therapeutic and/or prophylactic treatment of Alzheimer's disease.
  • a certain embodiment of the invention relates to a compound of formula I as described herein for the use in the therapeutic and/or prophylactic treatment of diabetes, particularly type 2 diabetes.
  • a certain embodiment of the invention relates to a method for the use in inhibition of BACEl and/or BACE2 activity, particularly for the therapeutic and/or prophylactic treatment of diseases and disorders characterized by elevated ⁇ -amyloid levels and/or ⁇ -amyloid oligomers and/or ⁇ -amyloid plaques and further deposits, Alzheimer's disease, diabetes or type 2 diabetes, which method comprises administering compound of formula I as described herein to a human being or animal.
  • the invention includes all optical isomers, i.e. diastereoisomers, diastereomeric mixtures, racemic mixtures, all their corresponding enantiomers and/or tautomers as well as their solvates.
  • the compounds of formula I may contain one or more asymmetric centers and can therefore occur as racemates, racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers. Additional asymmetric centers may be present depending upon the nature of the various substituents on the molecule. Each such asymmetric centre will independently produce two optical isomers and it is intended that all of the possible optical isomers and diastereomers in mixtures and as pure or partially purified compounds are included within this invention. The present invention is meant to encompass all such isomeric forms of these compounds. The independent syntheses of these diastereomers or their chromatographic separations may be achieved as known in the art by appropriate modification of the methodology disclosed herein.
  • optically pure enantiomer means that the compound contains > 90 % of the desired isomer by weight, preferably > 95 % of the desired isomer by weight, or more preferably > 99 % of the desired isomer by weight, said weight percent based upon the total weight of the isomer(s) of the compound.
  • Chirally pure or chirally enriched compounds may be prepared by chirally selective synthesis or by separation of enantiomers. The separation of enantiomers may be carried out on the final product or alternatively on a suitable intermediate.
  • the compounds of formula I may be prepared in accordance with the following schemes.
  • the starting material is commercially available or may be prepared in accordance with known methods. Any previously defined residues and variables will continue to have the previously defined meaning unless otherwise indicated.
  • Sulfmyl imines of general formula VI can be prepared in analogy to T.P. Tang & J.A. Ellman, J. Org. Chem. 1999, 64, 12, by condensation of an aryl ketone IV and a sulfonamide V, e.g. an alkyl sulfinamide, most preferably (R)-(+)-tert-butylsulfinamide in the presence of a Lewis acid such as e.g. a titanium(IV)alkoxide, more preferably titanium(IV)ethoxide in a solvent such as an ether, e.g. diethyl ether or more preferably THF.
  • a Lewis acid such as e.g. a titanium(IV)alkoxide, more preferably titanium(IV)ethoxide in a solvent such as an ether, e.g. diethyl ether or more preferably THF.
  • the conversion of the sulfmyl imine VI to the sulfinamide ester VII proceeds stereoselective ⁇ by the chiral directing group as described by Tang & Ellman.
  • the sulfmyl imine VI can be reacted in a Reformatsky reaction with a zinc enolate generated from e.g. an alkyl bromodifluoroacetate, preferably ethyl bromodifluoroacetate, activated zinc powder at ambient to elevated temperature, preferably at 23 to 60 °C in a solvent such as an ether, e.g. diethyl ether or more preferably THF.
  • Alcohol VIII can be prepared by the reduction of the ethylester VII with an alkali hydride, preferably lithium borohydride or lithium aluminium hydride in a solvent such as an ether, e.g. diethyl ether or more preferably THF.
  • an alkali hydride preferably lithium borohydride or lithium aluminium hydride in a solvent such as an ether, e.g. diethyl ether or more preferably THF.
  • Hydrolysis of the chiral directing group in the sulfinamide alcohol VIII to give the aminoalcohol IX can be accomplished with a mineral acid, e.g. sulfuric acid or preferably hydrochloric acid in a solvent such as an ether, e.g. diethyl ether, THF or more preferably 1,4- dioxane.
  • a mineral acid e.g. sulfuric acid or preferably hydrochloric acid
  • a solvent such as an ether, e.g. diethyl ether, THF or more preferably 1,4- dioxane.
  • Difluoro-aminooxazines X can be prepared by reaction of aminoalcohol IX with cyanogen bromide in a solvent such as an alcohol, preferably ethanol.
  • the reduction of the nitro group in the aminooxazine X to the aniline XI can be accomplished by hydrogenation using a catalysts such as Pd/C in protic solvents, such as alcohols, perferrably ethanol or methanol.
  • a catalysts such as Pd/C
  • protic solvents such as alcohols, perferrably ethanol or methanol.
  • Selective amide coupling of the aniline XI and a carboxylic acid to give the amide XIII can be effected with 4-(4,6-dimethoxy[1.3.5]triazin-2-yl)-4-methylmorpholinium chloride (DMTMM) hydrate in a solvent such as methanol.
  • DTMM 4-(4,6-dimethoxy[1.3.5]triazin-2-yl)-4-methylmorpholinium chloride
  • iodonium donating systems using iodides as an iodide source, like e.g. ammonium iodide, together with a strong oxidising agent, like e.g. hydrogen peroxide, in a polar solvent, like e.g. acetic acid, and as described by N. Narender et al. in Tetrahedron Letters 48 (2007) 6
  • P 1 e.g. Tr, MMTr, DMTr, TMTr
  • Sulfmyl imines of general formula XVI can be prepared in analogy to the description mentioned above for the preparation of sulfmyl imines of general formula VI.
  • the conversion of the sulfmyl imine XVI to the sulfanamide ester XVII proceeds in an analogous manner as previously described for the preparation of sulfanamide ester VII.
  • the alcohol of general formula XIX, wherein R 4 and R 5 are hydrogen, can be prepared again in an analogous manner as described above for the alcohol VIII.
  • the alcohols of general formula XVIII, wherein R 4 and R 5 are Ci_7-alkyl can be prepared by reacting the sulfmamide ester XVII with an excess of an organometallic reagent bearing the corresponding Ci_7-alkyl groups, such as a Ci_7-alkyllithium or Ci_7-alkylmagnesium halide compound, in etheral solvents, such as diethyl ether or THF, at temperatures between -78 °C and ambient temperature. Hydrolysis of the chiral directing group in the sulfanamide alcohols of general formula XVIII proceeds in an analogous manner as described above for the sulfinamide ester VIII to give here the aminoalcohol XIX.
  • Aminooxazines of general formula XX can again be prepared as described above by reaction of aminoalcohol XIX with cyanogen bromide in a solvent such as an alcohol, preferably ethanol.
  • the protection of the amino group in compounds of general formula XX to produce aryl bromides of general formula XXI can be performed with triarylmethyl chlorides, such as triphenylmethyl chloride (Tr-Cl), p-methoxyphenyldiphenylmethyl chloride (MMTr-Cl), di(p- methoxyphenyl)phenylmethyl chloride (DMTr-Cl) or tri(p-methoxyphenyl)methyl chloride (TMTr-Cl), preferably DMTr-Cl, under basic conditions, e.g. in the presence of an amine, such as triethylamine or diisopropylethylamine, in a chlorinated solvent, such as dichloromethane or chloroform, at temperatures between 0 °C and ambient temperature.
  • triarylmethyl chlorides such as triphenylmethyl chloride (Tr-Cl), p-methoxyphenyldiphenylmethyl chloride (MMTr-Cl),
  • Aryl bromides of general formula XXI can be reacted with ammonia equivalents, such as benzophenone imine, in the presence of a suitable transition metal catalyst, such as bis(dibenzylideneacetone)palladium (0) ((dba) 2 Pd) or tris(dibenzylideneacetone)dipalladium (0) ((dba) 3 Pd 2 )), and a suitable ligand, such as rac-2,2'-bis(diphenylphosphino)-l, -binaphthyl (rac- BINAP), 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (X-PHOS) or 2-di-tert- butylphosphino-2',4',6'-triisopropylbiphenyl (t-Bu X-phos), in the presence of a base, such as sodium tert-butoxide
  • Deprotection of both amino groups in compounds of general formula XXII can be achieved by a one-pot procedure by first reacting it with a strong organic acid, such as trifluoro acetic acid, in chlorinated solvents, such as dichloromethane or chloroform, under anhydrous conditions at temperatures between 0 °C and ambient temperature to cleave the P'-group, then by addition of water to cleave the benzophenone imine and reaction at ambient temperature to produce diamines of general formula XI, which can be transformed to compounds of general formula I as described above.
  • a strong organic acid such as trifluoro acetic acid
  • chlorinated solvents such as dichloromethane or chloroform
  • Selective cleavage of one of the tert-butoxy carbonyl groups in compounds of general formula XXIII can be performed by acid, such as trifluoro acetic acid, to produce compounds of general formula XXIV together with small amounts of compounds of general formula X.
  • the reduction of the nitro group in the aminooxazine XXIV to the aniline XXV can be accomplished by hydrogenation using a catalysts such as Pd/C in protic solvents, such as alcohols, perferrably ethanol or methanol.
  • a catalysts such as Pd/C in protic solvents, such as alcohols, perferrably ethanol or methanol.
  • Amide coupling of the aniline XXV and a carboxylic acid to give the amides of general formula XXVI can be effected in a solvent such as methanol with 4-(4,6- dimethoxy[1.3.5]triazin-2-yl)-4-methylmorpholinium chloride hydrate (DMTMM) or other condensating agents, such as 0-(benzotriazol-l-yl)-N,N,N',N'-tetramethyluronium.- hexafluorophosphate (HBTU) or 0-(7-azabenzotriazol-l-yl)- ⁇ , ⁇ , ⁇ ', ⁇ '-tetramethyluronium- hexafluorophosphate (HATU), in the presence of an amine, such as triethylamine or diisopropylethylamine, in a solvent, such as acetonitrile or ⁇ , ⁇ -dimthylformamide, at temperatures between 0 °C
  • the cleavage of the protecting tert-butoxy carbonyl group in compounds of general formula XXVI to produce compounds of general formula I can be effected by acid, such as trifluoro acetic acid, in inert solvents, such as dichloromethane, at temperatures between 0 °C and ambient temperature.
  • acid such as trifluoro acetic acid
  • inert solvents such as dichloromethane
  • the corresponding pharmaceutically acceptable salts with acids can be obtained by standard methods known to the person skilled in the art, e.g. by dissolving the compound of formula I in a suitable solvent such as e.g. dioxan or THF and adding an appropriate amount of the corresponding acid.
  • a suitable solvent such as e.g. dioxan or THF
  • the products can usually be isolated by filtration or by chromatography.
  • the conversion of a compound of formula I into a pharmaceutically acceptable salt with a base can be carried out by treatment of such a compound with such a base.
  • One possible method to form such a salt is e.g. by addition of 1/n equivalents of a basic salt such as e.g.
  • a suitable solvent e.g. ethanol, ethanol-water mixture, tetrahydrofuran- water mixture
  • the compounds of formula I and their pharmaceutically acceptable salts possess valuable pharmacological properties. It has been found that the compounds of the present invention are associated with inhibition of BACE1 and/or BACE2 activity. The compounds were investigated in accordance with the test given hereinafter.
  • Cellular ⁇ -lowering assay Human HEK293 cells which are stably transfected with a vector expressing a cDNA of the human APP wt gene (APP695) were used to assess the potency of the compounds in a cellular assay.
  • the cells were seeded in 96-well microtiter plates in cell culture medium (Iscove, plus 10% (v/v) fetal bovine serum, glutamine, penicillin/streptomycin) to about 80% confluence and the compounds were added at a lOx concentration in 1/10 volume of medium without FCS containing 8% DMSO (final concentration of DMSO was kept at 0.8% v/v).
  • Assay for BACE inhibition by measuring cellular TMEM27 cleavage uses the principle of inhibition of human TMEM27 cleavage by endogenous cellular BACE2 in the Insle rat cell line and shedding from the cell surface into the culture medium, followed by detection in an ELISA assay. Inhibition of BACE2 prevents the cleavage and shedding in a dose-dependent manner.
  • the stable cell line "INS-TMEM27” represents an INSle-derived cell line with inducible expression (using the TetOn system) of full-length hTMEM27 in a doxycycline-dependent manner.
  • the cells are cultured throughout the experiment in RPMI1640 + Glutamax (Invitrogen) Penicillin/Streptomycin, 10% Fetal bovine serum, 100 mM pyruvate, 5 mM beta- mercatptoethanol, 100 micrograms/ml G418 and 100 microgram ml hygromycin and are grown inadherent culture at 37 °C in a standard C0 2 cell culture incubator.
  • INS-TMEM27 cells are seeded in 96-well plates.
  • BACE2 inhibitor is added in a range of concentrations as required by the assay and after a further two hours, doxycycline is added to a final concentration of 500 ng/ml.
  • the cells are incubated for a further 46 hours and the supernatant harvested for detection of shed TMEM27.
  • An ELISA assay (using a pair of mouse anti-human-TMEM27 antibodies, raised against the extracellular domain of TMEM27) is used for detection of TMEM27 in the culture medium.
  • An EC50 for BACE2 inhibition is calculated using the ELISA readout for each inhibitor concentration with standard curve-fitting software such as XLFit for the Excel spreadsheet rogram.
  • Table 1 IC50 values of selected examples CYP inhibition assay
  • cytochromes P450 2C9, 2D6 and 3A4 was assessed using human liver microsomes and CYP-selective substrate metabolism reactions. 50 ⁇ incubations were made up containing (finally) 0.2 mg/ml pooled human liver microsomes, 5 ⁇ substrate (diclofenac for CYP2C9 [4 'hydroxylase], dextromethorphan for CYP2D6 [O-demethylase] or midazolam for CYP3A4 [1 'hydroxylase]), 0.25 ⁇ _, DMSO containing test inhibitor and NADPH regenerating system.
  • CYPs cytochromes P450
  • Test inhibitor concentrations of 50, 16.7, 5.6, 1.9, 0.6 and 0.2 ⁇ were assessed in singlicate. Incubations were prewarmed to 37 °C for 10 minutes before initiation by addition of NADPH regenerating system. Incubations were quenched after 5 minutes (20 minutes for dextromethorphan) by addition of 50 ⁇ cold acetonitrile containing 20 ng/ml 4-OH-diclofenac- 13C6, 20 ng/mL dextrorphan-D3 and 20 ng/mL l-OH-midazolam-D4. Quenched incubates were stored at -20 °C for at least 1 hour before centrifugation (20,000x g, 20 minutes).
  • PatchXpress hERG Inhibition Assay The detailed method to quantify hERG channel inhibition by the automated patch clamp system PatchXpress ® 7000A (Molecular Devices, Sunnyvale, CA) has been described by Guo et al. (Guo L, Guthrie H, Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation. Journal of Pharmacological & Toxicological Methods, (2005) 52(1): 123-35).
  • CHO cells transfected with the human ether-a- go-go-related gene was cultured in Ex-cell 302 media supplemented with 10% fetal bovine serum, 2 mM glutamine and 0.25 mg/ml geneticin and maintained in a C0 2 incubator at 37 °C.
  • the external buffer contained (in mM): 150 NaCl, 10 Hepes, 4 KC1, 1.2 CaCl 2 , 1 MgCl 2 , pH 7.4 adjusted with HC1 and the internal recording solution contained (in mM): 140 KC1, 6 EGTA, 5 Hepes, MgCl 2 , 5 ATP-Na 2 , pH 7.2 adjusted with KOH.
  • the membrane potential was then clamped at -80 mV and the hERG channel activated by a 1 -second depolarizing pulse delivered at 0.1 Hz, the hERG current was measured during the 500 ms-repolarizing pulse to -40 mV.
  • the cell was first exposed to 0.3% DMSO as the vehicle control, followed by the test article in three ascending, full- log interval concentrations and finally E-4031 at 1 ⁇ (as the positive control) to block the hERG current completely.
  • Each test article was tested on three or more cells and at concentrations up to 30 ⁇ or the solubility limit determined the BD GentestTM solubility scanner.
  • the inhibition of hERG current at each concentration was normalized to that recorded in the vehicle control, and fitted with Hill equation to calculate IC 2 o
  • the MR121 fluorescence assays described below are based on the fact that MR121 forms a non- fluorescent ground state complex with tryptophan. In solution this formation occurs at millimolar concentrations of tryptophan.
  • the mechanism can be used to design a generic biochemical assay for proteases.
  • a substrate peptide is labeled at the N-terminus with tryptophan and at the C-terminus with the fluorophore MR121 (for cathepsin D the 10 amino acid peptide WTSVLMAAPC-MR121 was used; for cathepsin E, MR121-CKLVFFAEDW was used).
  • the substrates remain intact and the MR121 fluorescence is reduced by the high local Trp-concentration. If the substrates are cleaved by the enzymes the MR121 fluorescence is recovered.
  • the fluorescent substrate cathepsin D and cathepsin E kinetic assays were performed at room temperature in 384-well micro titer plates (black with clear flat bottom, non binding surface plates from Corning) in a final volume of 51 ⁇ 1.
  • the test compounds were serially diluted in DMSO (15 concentrations, 1/3 dilution steps) and ⁇ of diluted compounds were mixed for 10 min with 40 ⁇ of cathepsin D (from human liver, Calbiochem) diluted in assay buffer (100 mM sodium acetate, 0.05% BSA, pH 5.5; final concentration: 200 nM) or with 40 ⁇ of recombinant human cathepsin E (R&D Systems) diluted in assay buffer (100 mM sodium acetate, 0.05% BSA, pH 4.5; final concentration: 0.01 nM).
  • LLC-PK1 cell line (ATCC #CL-101) is a porcine kidney epithelial cell line .
  • MDR1 Human multidrug resistance protein 1 transfected cell lines were obtained from Dr. A. Schinkel, The Netherlands Cancer Institute (Amsterdam, The Netherlands). All cell lines were cultured on permeable inserts (Costar, 0.33 cm 2 area, pore size 3.0 ⁇ , low density) at 4.5 ⁇ 10 5 cells/cm 2 . Transport measurements were performed at day 4 after seeding. Tightness of the cell monolayer was controlled via the permeability of the extracellular marker lucifer yellow (10 ⁇ ). A detailed description of the method was reported by Schwab et al. (Schwab D, Schrag P, Portmann R, Ruhmann S.
  • LLC-PK1 cell lines parental and transfected with human (MDR1) or mouse (mdrla) P glycoprotein to study transcellular transport by P- glycoprotein. Report No. 1008708. July 01, 2002. and Schwab D, Schrag P, Portmann R. Validation report on in vitro P-glycoprotein transport of 16 reference compounds in LLC-PK1 cells (parental) and MDR1 or mdrla (Mouse multidrug resistance protein la) transfected LLC- PK1 cells and correlation to in vivo brain penetration in mice. Report No. 1008771. August 21, 2002.). Experiments showing lucifer yellow permeation superior to 1 %/h were rejected.
  • P app , A, Co, and dQIdt represent the apparent permeability, the filter surface area, the initial concentration, and the amount transported per time period, respectively.
  • P app values were calculated on the basis of a single time point (2 h).
  • P app BA is the permeability value in the basolateral-to-apical direction
  • P app AB the permeability value in the apical-to-basolateral direction.
  • P app were not corrected for flux of the extracellular marker lucifer yellow, which was used to assess the quality of the cell monolayers.
  • A less than 50% of control @ 30 mg/kg p.o.
  • the compounds of formula I and the pharmaceutically acceptable salts can be used as therapeutically active substances, e.g. in the form of pharmaceutical preparations.
  • the pharmaceutical preparations can be administered orally, e.g. in the form of tablets, coated tablets, dragees, hard and soft gelatine capsules, solutions, emulsions or suspensions.
  • the administration can, however, also be effected rectally, e.g. in the form of suppositories, or parenterally, e.g. in the form of injection solutions.
  • the compounds of formula I and the pharmaceutically acceptable salts thereof can be processed with pharmaceutically inert, inorganic or organic carriers for the production of pharmaceutical preparations.
  • Lactose, corn starch or derivatives thereof, talc, stearic acids or its salts and the like can be used, for example, as such carriers for tablets, coated tablets, dragees and hard gelatine capsules.
  • Suitable carriers for soft gelatine capsules are, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols and the like. Depending on the nature of the active substance no carriers are however usually required in the case of soft gelatine capsules.
  • Suitable carriers for the production of solutions and syrups are, for example, water, polyols, glycerol, vegetable oil and the like.
  • Suitable carriers for suppositories are, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols and the like.
  • the pharmaceutical preparations can, moreover, contain pharmaceutically acceptable auxiliary substances such as preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.
  • pharmaceutically acceptable auxiliary substances such as preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.
  • Medicaments containing a compound of formula I or a pharmaceutically acceptable salt thereof and a therapeutically inert carrier are also an object of the present invention, as is a process for their production, which comprises bringing one or more compounds of formula I and/or pharmaceutically acceptable salts thereof and, if desired, one or more other therapeutically valuable substances into a galenical administration form together with one or more therapeutically inert carriers.
  • the dosage can vary within wide limits and will, of course, have to be adjusted to the individual requirements in each particular case.
  • the dosage for adults can vary from about 0.01 mg to about 1000 mg per day of a compound of general formula I or of the corresponding amount of a pharmaceutically acceptable salt thereof.
  • the daily dosage may be administered as single dose or in divided doses and, in addition, the upper limit can also be exceeded when this is found to be indicated.
  • the following examples illustrate the present invention without limiting it, but serve merely as representative thereof.
  • the pharmaceutical preparations conveniently contain about 1- 500 mg, preferably 1-100 mg, of a compound of formula I. Examples of compositions according to the invention are:
  • the compound of formula I, lactose and corn starch are firstly mixed in a mixer and then in a comminuting machine.
  • the mixture is returned to the mixer; the talc is added thereto and mixed thoroughly.
  • the mixture is filled by machine into suitable capsules, e.g. hard gelatine capsules.
  • the compound of formula I is dissolved in a warm melting of the other ingredients and the mixture is filled into soft gelatin capsules of appropriate size.
  • the filled soft gelatin capsules are treated according to the usual procedures.
  • the suppository mass is melted in a glass or steel vessel, mixed thoroughly and cooled to
  • the compound of formula I is dissolved in a mixture of Polyethylene Glycol 400 and water for injection (part).
  • the pH is adjusted to 5.0 by acetic acid.
  • the volume is adjusted to 1.0 ml by addition of the residual amount of water.
  • the solution is filtered, filled into vials using an appropriate overage and sterilized.
  • the compound of formula I is mixed with lactose, microcrystalline cellulose and sodium carboxymethyl cellulose and granulated with a mixture of polyvinylpyrrolidone in water.
  • the granulate is mixed with magnesium stearate and the flavoring additives and filled into sachets.
  • methylmagnesium bromide (3 M in diethyl ether, 11.6 ml, 34.9 mmol)) was dropwise added and stirring was continued -78 °C for 4 h, followed by warming up to 23 °C and stirring for another 18 h.
  • the reaction mixture was poured into sat. NH 4 Cl-solution, extracted with ethyl acetate, the organic layer was washed with brine and dried over Na 2 S0 4 , filtered and the solvent was evaporated totally to give the product (1.29 g, 86 %) as light yellow oil.
  • the 5-(2,2,2-trifluoro-ethoxy)-pyridine-2-carboxylic acid was obtained as follows: a) 5-(2,2,2-Trifluoro-ethoxy)-pyridine-2-carboxylic acid methyl ester
  • the 5-(2,2,3,3-tetrafluoro-propoxy)-pyridine-2-carboxylic acid was prepared as follows: a) 5-(2,2,3,3-Tetrafluoro-propoxy)-pyridine-2-carboxylic acid methyl ester A solution of 5-hydroxy-pyridine-2-carboxylic acid methyl ester (2.0 g, 13.1 mmol) in acetone (40 ml) was treated with potassium carbonate (5.415g, 39.2 mmol) and trifluoro- methanesulphonic acid 2,2,3,3-tetrafluoropropyl ester. After 4 hours stirring at room temperature the suspension was diluted with diethylether.
  • 6- Chloro-pyridazine-3-carboxylic acid [3-((R)-2-amino-5,5-difluoro-4,6,6-trimethyl-5,6- dihydro-4H-[l,3]oxazin-4-yl)-4-fluoro-phenyl]-amide and example 37a) 6-Chloro- pyridazine-3-carboxylic acid [3-((R)-2-amino-5,5-difluoro-4,6,6-trimethyl-5,6-dihydro-4H- [l,3]oxazin-4-yl)-4-fluoro-phenyl]-amide hydrochloride
  • the 5-(2,2,3,3,3-pentafluoro-propoxy)-pyridine-2-carboxylic acid was obtained as follows: a) In a manner analogous to that described in example 30 a), the alkylation of the 5- hydroxy-pyridine-2-carboxylic acid methyl ester with potassium carbonate and trifluoro- methanesulphonic acid 2,2,3,3,3-pentafluoropropyl ester yielded the 5-(2,2,3,3,3-pentafluoro- propoxy)-pyridine-2-carboxylic acid methyl ester as a light yellow oil.
  • MS (ISP): m/z 285 [M] + .
  • the 3-(2,2,2-trifluoro-ethoxy)-pyridine-2-carboxylic acid was prepared as follows: a) To a solution of 3-hydroxy-pyridine-2-carboxylic acid methyl ester (200 mg, 1.3 mmol) in N,N-dimethylformamide (2.0 ml) was added at 22 °C sodium hydride (55% in oil, 64 mg) and stirring was continued until gas evolution ceased. The suspension was cooled to 0 °C and treated with trifluoro ethyl trifluormethanesulfonate (728 mg) and stirring was continued at 22 °C for 2 hours.
  • the 4-chloro-5-cyclopropyl-2H-pyrazole-3-carboxylic acid was obtained as follows: a) To a solution of 5-cyclopropyl-2H-pyrazole-3-carboxylic acid ethyl ester (202 mg) in N,N-dimethylformamide (4 ml) was added at 0°C N-chlorosuccinimide (199 mg) and stirring was continued at 22°C for 15 hours.
  • the 4-chloro-l-difluoromethyl-lH-pyrazole-3-carboxylic acid was obtained as follows: a) l-Difluoromethyl-lH-pyrazole-3-carboxylic acid methyl ester A solution of l-difluoromethyl-lH-pyrazole-3-carboxylic acid (CAS925179-02-8) (500 mg,
  • the 5-cyano-l-oxy-pyridine-2-carboxylic acid was obtained as follows:
PCT/EP2010/068912 2009-12-11 2010-12-06 2-amino-5, 5-difluoro-5, 6-dihydro-4h-oxazines as bace 1 and/or bace 2 inhibitors WO2011069934A1 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
UAA201208098A UA103272C2 (uk) 2009-12-11 2010-06-12 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2
AU2010330031A AU2010330031B2 (en) 2009-12-11 2010-12-06 2-Amino-5, 5-difluoro-5, 6-dihydro-4H-oxazines as BACE 1 and/or BACE 2 inhibitors
MA34922A MA34779B1 (fr) 2009-12-11 2010-12-06 2-amino-5,5-difluoro-5,6-dihydro-4h-oxazines en tant qu'inhibiteurs de bace 1 et/ou bace2
BR112012013175A BR112012013175A2 (pt) 2009-12-11 2010-12-06 2-amino-5,5-diflúor-5,6-di-hidro-4h-oxazinas como inibidores de bace 1 e/ou bace 2
MX2012006493A MX2012006493A (es) 2009-12-11 2010-12-06 Derivados de 2-amino-5,5-difluor-5, 6-dihidro-4h-[1,3]oxazin-4-il) -fenil]-amida como inhibidores de la bace1 y/o bace2.
RU2012126989/04A RU2515221C2 (ru) 2009-12-11 2010-12-06 2-амино-5,5-дифтор-5,6-дигидро-4н-оксазины в качестве ингибиторов васе 1 и(или) васе 2
IN3043DEN2012 IN2012DN03043A (uk) 2009-12-11 2010-12-06
SG2012042560A SG181610A1 (en) 2009-12-11 2010-12-06 2-amino-5, 5-difluoro-5, 6-dihydro-4h-oxazines as bace 1 and/or bace 2 inhibitors
NZ599008A NZ599008A (en) 2009-12-11 2010-12-06 2-amino-5, 5-difluoro-5, 6-dihydro-4h-oxazines as bace 1 and/or bace 2 inhibitors
KR1020127017919A KR101506773B1 (ko) 2009-12-11 2010-12-06 Ｂａｃｅ 1 및/또는 ｂａｃｅ 2 억제제로서의 2-아미노-5,5-다이플루오로-5,6-다이하이드로-4ｈ-옥사진
EP10785437A EP2509965A1 (en) 2009-12-11 2010-12-06 2-amino-5, 5-difluoro-5, 6-dihydro-4h-oxazines as bace 1 and/or bace 2 inhibitors
CN2010800561519A CN102712609A (zh) 2009-12-11 2010-12-06 作为bace1和/或bace2抑制剂的2-氨基-5,5-二氟-5,6-二氢-4h-噁嗪类
CA2776727A CA2776727C (en) 2009-12-11 2010-12-06 2-amino-5,5-difluoro-5,6-dihydro-4h-oxazines as bace 1 and/or bace 2 inhibitors
JP2012542481A JP5584778B2 (ja) 2009-12-11 2010-12-06 Ｂａｃｅ１及び／又はｂａｃｅ２阻害剤としての２−アミノ−５，５−ジフルオロ−５，６−ジヒドロ−４ｈ−オキサジン
IL219107A IL219107A (en) 2009-12-11 2012-04-05 2-Amino-5,5-Dipluoro-6,5-Dihydro-4 H-Oxazines as 1bace and / or 2bace inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09178983 2009-12-11
EP09178983.4 2009-12-11

Publications (1)

Publication Number Publication Date
WO2011069934A1 true WO2011069934A1 (en) 2011-06-16

Family

ID=43585547

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/068912 WO2011069934A1 (en) 2009-12-11 2010-12-06 2-amino-5, 5-difluoro-5, 6-dihydro-4h-oxazines as bace 1 and/or bace 2 inhibitors

Country Status (25)

Country Link
US (1) US8389513B2 (uk)
EP (1) EP2509965A1 (uk)
JP (1) JP5584778B2 (uk)
KR (1) KR101506773B1 (uk)
CN (1) CN102712609A (uk)
AR (1) AR079327A1 (uk)
AU (1) AU2010330031B2 (uk)
BR (1) BR112012013175A2 (uk)
CA (1) CA2776727C (uk)
CL (1) CL2012001464A1 (uk)
CO (1) CO6541656A2 (uk)
CR (1) CR20120262A (uk)
EC (1) ECSP12011961A (uk)
IL (1) IL219107A (uk)
IN (1) IN2012DN03043A (uk)
MA (1) MA34779B1 (uk)
MX (1) MX2012006493A (uk)
MY (1) MY169962A (uk)
NZ (1) NZ599008A (uk)
PE (1) PE20121500A1 (uk)
RU (1) RU2515221C2 (uk)
SG (1) SG181610A1 (uk)
TW (1) TWI487704B (uk)
UA (1) UA103272C2 (uk)
WO (1) WO2011069934A1 (uk)

Cited By (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168630B2 (en) 2007-04-24 2012-05-01 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives substituted with a cyclic group
US8173642B2 (en) 2005-10-25 2012-05-08 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives
WO2012071279A1 (en) 2010-11-23 2012-05-31 Amgen Inc. Spiro-amino-imidazolone and spiro-amino-dihydro-pyrimidinone compounds as beta-secretase modulators and methods of use
US8207164B2 (en) 2009-07-24 2012-06-26 Novartis Ag Oxazine derivatives and their use in the treatment of neurological disorders
WO2012107371A1 (en) 2011-02-08 2012-08-16 F. Hoffmann-La Roche Ag N-[3-(5-amino-3,3a,7,7a-tetrahydro-1h-2,4-dioxa-6-aza-inden-7-yl)-phenyl]-amides as bace1 and/or bace2 inhibitors
WO2012147763A1 (ja) 2011-04-26 2012-11-01 塩野義製薬株式会社 オキサジン誘導体およびそれを含有するｂａｃｅ１阻害剤
WO2012156284A1 (en) * 2011-05-16 2012-11-22 F. Hoffmann-La Roche Ag 1,3-oxazines as bace1 and/or bace2 inhibitors
WO2012168164A1 (en) * 2011-06-07 2012-12-13 F. Hoffmann-La Roche Ag Halogen-alkyl-1,3 oxazines as bace1 and/or bace2 inhibitors
WO2012168175A1 (en) * 2011-06-07 2012-12-13 F. Hoffmann-La Roche Ag [1,3]oxazines
US8338413B1 (en) 2012-03-07 2012-12-25 Novartis Ag Oxazine derivatives and their use in the treatment of neurological disorders
WO2013027188A1 (en) 2011-08-25 2013-02-28 Novartis Ag 2 -amino-4 - (pyridin- 2 -yl) - 5, 6 -dihydro-4h- 1, 3 -oxazine derivatives and their use as bace-1 and/or bace - 2 inhibitors
WO2013041499A1 (en) * 2011-09-21 2013-03-28 F. Hoffmann-La Roche Ag N-(3-(2-amino-6,6-difluoro-4,4a,5,6,7,7a-hexahydro-cyclopenta[e][1,3]oxazin-4-yl)-phenyl)-amides as bace1 inhibitors
WO2013110622A1 (en) 2012-01-26 2013-08-01 F. Hoffmann-La Roche Ag Fluoromethyl-5,6-dihydro-4h-[1,3]oxazines
US8524897B2 (en) 2011-01-12 2013-09-03 Novartis Ag Crystalline oxazine derivative
WO2013142613A1 (en) 2012-03-20 2013-09-26 Elan Pharmaceuticals, Inc. Spirocyclic dihydro-thiazine and dihydro-oxazine bace inhibitors, and compositions and uses thereof
US8557826B2 (en) 2009-10-08 2013-10-15 Merck Sharp & Dohme Corp. Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions, and their use
US8563543B2 (en) 2009-10-08 2013-10-22 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
US8569310B2 (en) 2009-10-08 2013-10-29 Merck Sharp & Dohme Corp. Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions and their use
WO2013174781A1 (en) 2012-05-24 2013-11-28 F. Hoffmann-La Roche Ag 5-amino[1,4]thiazines as bace 1 inhibitors
WO2014001228A1 (en) * 2012-06-26 2014-01-03 F. Hoffmann-La Roche Ag Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors
US8637508B2 (en) 2011-01-13 2014-01-28 Novartis Ag Heterocyclic derivatives and their use in the treatment of neurological disorders
US8637504B2 (en) 2008-06-13 2014-01-28 Shionogi & Co., Ltd. Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity
US8653067B2 (en) 2007-04-24 2014-02-18 Shionogi & Co., Ltd. Pharmaceutical composition for treating Alzheimer's disease
JP2014508751A (ja) * 2011-02-18 2014-04-10 エフ．ホフマン−ラ ロシュ アーゲー Ｂａｃｅ１及び／又はｂａｃｅ２阻害剤としての１，４−オキサゼピン類
WO2014059185A1 (en) 2012-10-12 2014-04-17 Amgen Inc. Amino - dihydrothiazine and amino - dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use
WO2014056816A1 (en) 2012-10-10 2014-04-17 F. Hoffmann-La Roche Ag COMBINATION OF AN Aβ ANTIBODY AND A BACE INHIBITOR
US8703785B2 (en) 2008-10-22 2014-04-22 Shionogi & Co., Ltd. 2-aminopyrimidin-4-one and 2-aminopyridine derivatives both having BACE1-inhibiting activity
WO2014065434A1 (en) * 2012-10-24 2014-05-01 Shionogi & Co., Ltd. Dihydrooxazine or oxazepine derivatives having bace1 inhibitory activity
JP2014510769A (ja) * 2011-04-11 2014-05-01 エフ．ホフマン−ラ ロシュ アーゲー Ｂａｃｅ１及び／又はｂａｃｅ２阻害剤としての１，３−オキサジン
US8729071B2 (en) 2009-10-08 2014-05-20 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as BACE inhibitors, compositions and their use
JP2014515382A (ja) * 2011-05-27 2014-06-30 エフ．ホフマン−ラ ロシュ アーゲー Ｂａｃｅ１及び／又はｂａｃｅ２阻害剤としてのスピロ−［１，３］−オキサジン及びスピロ−［１，４］−オキサゼピン誘導体
WO2014120658A1 (en) 2013-01-29 2014-08-07 Amgen Inc. Fused multicyclic 3-amino-5,6-dihydro-2h-1,4-thiazine derivatives and their use as beta-secretase inhibitors
WO2014134341A1 (en) 2013-03-01 2014-09-04 Amgen Inc. Perfluorinated 5,6-dihydro-4h-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use
WO2014138484A1 (en) 2013-03-08 2014-09-12 Amgen Inc. Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use
WO2014173917A1 (en) * 2013-04-26 2014-10-30 F. Hoffmann-La Roche Ag Synthesis of bace1 inhibitors
US8927721B2 (en) 2010-10-29 2015-01-06 Shionogi & Co., Ltd. Naphthyridine derivative
WO2015017407A1 (en) 2013-07-30 2015-02-05 Amgen Inc. Bridged bicyclic amino thiazine dioxide compounds as inhibitors of beta- secretase
US8999980B2 (en) 2009-12-11 2015-04-07 Shionogi & Co., Ltd. Oxazine derivatives
US9018219B2 (en) 2010-10-29 2015-04-28 Shionogi & Co., Ltd. Fused aminodihydropyrimidine derivative
US9145426B2 (en) 2011-04-07 2015-09-29 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
WO2015156421A1 (en) 2014-04-11 2015-10-15 Shionogi & Co., Ltd. Dihydrothiazine and dihydrooxazine derivatives having bace1 inhibitory activity
US9181236B2 (en) 2011-08-22 2015-11-10 Merck Sharp & Dohme Corp. 2-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use
US9221839B2 (en) 2011-04-07 2015-12-29 Merck Sharp & Dohme Corp. C5-C6 oxacyclic-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
WO2016150785A1 (en) 2015-03-20 2016-09-29 F. Hoffmann-La Roche Ag Bace1 inhibitors
US9499502B2 (en) 2011-04-13 2016-11-22 Merck Sharp & Dohme Corp. 5-substituted iminothiazines and their mono- and dioxides as BACE inhibitors, compositions, and their use
US9550762B2 (en) 2014-08-08 2017-01-24 Amgen, Inc. Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use
WO2017061534A1 (en) 2015-10-08 2017-04-13 Shionogi & Co., Ltd. Dihydrothiazine derivatives
US9751886B2 (en) 2013-06-12 2017-09-05 Janssen Pharmaceutica Nv 4-amino-6-phenyl-6,7-dihydro[1,2,3]triazolo[1,5-A]pyrazine derivatives as inhibitors of beta-secretase (BACE)
US9828350B2 (en) 2010-06-09 2017-11-28 Janssen Pharmaceutica Nv 5,6-dihydro-2H-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (BACE)
US9834559B2 (en) 2013-06-12 2017-12-05 Janssen Pharmaceutica Nv 4-Amino-6-phenyl-5,6-dihydroimidazo[1,5-a]pyrazin-3(2H)-one derivatives as inhibitors of beta-secretase (BACE)
US9840507B2 (en) 2010-12-22 2017-12-12 Janssen Pharmaceutica, Nv 5,6-dihydro-imidazo[1,2-a]pyrazin-8-ylamine derivatives useful as inhibitors of beta-secretase (BACE)
US9845326B2 (en) 2011-03-09 2017-12-19 Janssen Pharmaceutica Nv Substituted 3,4-dihydropyrrolo[1,2-A]pyrazines as beta-secretase (BACE) inhibitors
WO2018112083A1 (en) 2016-12-15 2018-06-21 Amgen Inc. Thiazine derivatives as beta-secretase inhibitors and methods of use
WO2018112084A1 (en) 2016-12-15 2018-06-21 Amgen Inc. Bicyclic thiazine and oxazine derivatives as beta-secretase inhibitors and methods of use
WO2018112081A1 (en) 2016-12-15 2018-06-21 Amgen Inc. Oxazine derivatives as beta-secretase inhibitors and methods of use
WO2018112086A1 (en) 2016-12-15 2018-06-21 Amgen Inc. Cyclopropyl fused thiazine derivatives as beta-secretase inhibitors and methods of use
US10106524B2 (en) 2014-12-18 2018-10-23 Janssen Pharmaceutica Nv 2,3,4,5-tetrahydropyridin-6-amine and 3,4-dihydro-2H-pyrrol-5-amine compound inhibitors of beta-secretase
US10246429B2 (en) 2015-08-06 2019-04-02 Amgen Inc. Vinyl fluoride cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use
US11021493B2 (en) 2016-12-15 2021-06-01 Amgen Inc. 1,4-thiazine dioxide and 1,2,4-thiadiazine dioxide derivatives as beta-secretase inhibitors and methods of use
US11447478B2 (en) 2013-04-11 2022-09-20 Hoffmann-La Roche Inc. BACE1 inhibitors
US11629154B2 (en) 2018-04-27 2023-04-18 Shionogi & Co., Ltd. Tetrahydropyranooxazine derivatives having selective BACE1 inhibitory activity

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI520943B (zh) 2011-01-25 2016-02-11 陶氏農業科學公司 用於製備４－胺基－３－氯－５－氟－６－（經取代的）吡啶甲酸酯的方法（二）
UA111749C2 (uk) * 2011-12-05 2016-06-10 Янссен Фармацевтика Нв Похідні 6-дифторметил-5,6-дигідро-2h-[1,4]оксазин-3-аміну
JO3318B1 (ar) 2013-06-18 2019-03-13 Lilly Co Eli مثبطات bace
CN110747276B (zh) * 2019-11-22 2020-06-30 山东大学齐鲁医院 Bace2作为胶质瘤预后/诊断/治疗标志物的应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006032851A1 (en) 2004-09-20 2006-03-30 Biolipox Ab Pyrazole compounds useful in the treatment of inflammation
WO2007049532A1 (ja) 2005-10-25 2007-05-03 Shionogi & Co., Ltd. アミノジヒドロチアジン誘導体
WO2008130320A2 (en) 2007-04-23 2008-10-30 Astrazeneca Ab Novel n- (8-heteroaryltetrahydronaphtalene-2yl) or n- (5- heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain
WO2008133274A1 (ja) 2007-04-24 2008-11-06 Shionogi & Co., Ltd. 環式基で置換されたアミノジヒドロチアジン誘導体
WO2008133273A1 (ja) 2007-04-24 2008-11-06 Shionogi & Co., Ltd. アルツハイマー症治療用医薬組成物
WO2009091016A1 (ja) 2008-01-18 2009-07-23 Eisai R & D Management Co., Ltd. 縮合アミノジヒドロチアジン誘導体
WO2009103626A1 (en) * 2008-02-18 2009-08-27 F. Hoffmann-La Roche Ag 4, 5-dihydro-oxazol-2-yl amine derivatives

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60003791T2 (de) * 1999-02-09 2004-02-05 The University Of Virginia Alumni Patents Foundation Felbamat-derivate
JP2005538177A (ja) * 2002-09-10 2005-12-15 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー アルツハイマー病処置用置換アミノエーテル化合物
WO2004043916A1 (en) * 2002-11-12 2004-05-27 Merck & Co., Inc. Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease
KR20060066057A (ko) * 2003-06-30 2006-06-15 다이이찌 세이야꾸 가부시기가이샤 복소환 메틸 설폰 유도체
WO2006041404A1 (en) * 2004-10-15 2006-04-20 Astrazeneca Ab Substituted amino-compounds and uses thereof
GB0912778D0 (en) * 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydro-oxazine derivatives
UY32799A (es) 2009-07-24 2011-02-28 Novartis Ag Derivados de oxazina y su uso en el tratamiento de trastornos neurológicos
US20120245155A1 (en) * 2009-12-11 2012-09-27 Shionogi & Co., Ltd. Fused heterocyclic compound having amino group

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006032851A1 (en) 2004-09-20 2006-03-30 Biolipox Ab Pyrazole compounds useful in the treatment of inflammation
WO2007049532A1 (ja) 2005-10-25 2007-05-03 Shionogi & Co., Ltd. アミノジヒドロチアジン誘導体
EP1942105A1 (en) * 2005-10-25 2008-07-09 Shionogi Co., Ltd. Aminodihydrothiazine derivative
WO2008130320A2 (en) 2007-04-23 2008-10-30 Astrazeneca Ab Novel n- (8-heteroaryltetrahydronaphtalene-2yl) or n- (5- heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain
WO2008133274A1 (ja) 2007-04-24 2008-11-06 Shionogi & Co., Ltd. 環式基で置換されたアミノジヒドロチアジン誘導体
WO2008133273A1 (ja) 2007-04-24 2008-11-06 Shionogi & Co., Ltd. アルツハイマー症治療用医薬組成物
EP2147914A1 (en) * 2007-04-24 2010-01-27 Shionogi&Co., Ltd. Aminodihydrothiazine derivatives substituted with cyclic groups
WO2009091016A1 (ja) 2008-01-18 2009-07-23 Eisai R & D Management Co., Ltd. 縮合アミノジヒドロチアジン誘導体
WO2009103626A1 (en) * 2008-02-18 2009-08-27 F. Hoffmann-La Roche Ag 4, 5-dihydro-oxazol-2-yl amine derivatives

Non-Patent Citations (48)

* Cited by examiner, † Cited by third party
Title
BARBIERO L. ET AL., EXP NEUROL., vol. 182, no. 2, August 2003 (2003-08-01), pages 335 - 45
BASSET C. ET AL., SCAND J IMMUNOL., vol. 51, no. 3, March 2000 (2000-03-01), pages 307 - 11
BIOCHEM. PHARMACOL., vol. 22, 1973, pages 3099
BROCKHAUS ET AL., NEUROREPORT, vol. 9, 1998, pages 1481 - 1486
DESNUES B. ET AL., CLIN VACCINE IMMUNOL., vol. 13, no. 2, February 2006 (2006-02-01), pages 170 - 8
G FINZI; F FRANZI; C PLACIDI; F ACQUATI ET AL.: "BACE2 is stored in secretory granules of mouse and rat pancreatic beta cells", ULTRASTRUCT PATHOL., vol. 32, no. 6, 2008, pages 246 - 251
GATCHEL J.R. ET AL., PROC NATL ACAD SCI U S A, vol. 105, no. 4, 29 January 2008 (2008-01-29), pages 1291 - 6
GREENBERG S.A. ET AL., ANN NEUROL., vol. 57, no. 5, May 2005 (2005-05-01), pages 664 - 78
GREENBERG S.A. ET AL., NEUROL, vol. 57, no. 5, May 2005 (2005-05-01), pages 664 - 78
GREWAL P.K. ET AL., MOL CELL BIOL., vol. 26, no. 13, July 2006 (2006-07-01), pages 4970 - 81
GUO L; GUTHRIE H: "Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation", JOURNAL OF PHARMACOLOGICAL & TOXICOLOGICAL METHODS, vol. 52, no. 1, 2005, pages 123 - 35
HARDY ET AL.: "The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics", SCIENCE, vol. 297, no. 5580, 19 July 2002 (2002-07-19), pages 353 - 6
HEDLUND M. ET AL., CANCER RES., vol. 68, no. 2, 15 January 2008 (2008-01-15), pages 388 - 94
HODGES A. ET AL., HUM MOL GENET., vol. 15, no. 6, 15 March 2006 (2006-03-15), pages 965 - 77
HOFFMEISTER A. ET AL., JOP, vol. 10, no. 5, 4 September 2009 (2009-09-04), pages 501 - 6
I HUSSAIN; D POWELL; D HOWLETT; G CHAPMAN ET AL.: "ASPl (BACE2) cleaves the amyloid precursor protein at the ?-secretase site", MOL CELL NEUROSCI., vol. 16, 2000, pages 609 - 619
J.F. HARTWING ET AL., ORGANIC LETTERS, vol. 3, no. 17, 2001, pages 2729 - 32
K FUKUI; Q YANG; Y CAO; N TAKAHASHI ET AL.: "The HNF-1 target Collectrin controls insulin exocytosis by SNARE complex formation", CELL METAB., vol. 2, 2005, pages 373 - 384
KIHARA Y. ET AL., PROC NATL ACAD SCI U S A., vol. 106, no. 51, 22 December 2009 (2009-12-22), pages 21807 - 12
KILJANSKI J. ET AL., THYROID., vol. 15, no. 7, July 2005 (2005-07-01), pages 645 - 52
KIM Y.J. ET AL., NEUROBIOL DIS., vol. 22, no. 2, May 2006 (2006-05-01), pages 346 - 56
KOISTINEN H. ET AL., MUSCLE NERVE., vol. 34, no. 4, October 2006 (2006-10-01), pages 444 - 50
KONDOH K. ET AL., BREAST CANCER RES TREAT., vol. 78, no. 1, March 2003 (2003-03-01), pages 37 - 44
LAGOS D. ET AL., BLOOD, vol. 109, no. 4, 15 February 2007 (2007-02-15), pages 1550 - 8
LI Q.X. ET AL., AGING CELL, vol. 5, no. 2, April 2006 (2006-04-01), pages 153 - 65
LICHTENTHALER S.F. ET AL., J BIOL CHEM., vol. 278, no. 49, 5 December 2003 (2003-12-05), pages 48713 - 9
LL BAGGIO; DJ DRUCKER: "Therapeutic approaches to preserve islet mass in type 2 diabetes", ANNU. REV. MED., vol. 57, 2006, pages 265 - 281
LUO ET AL.: "Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation", NAT NEUROSCI., vol. 4, no. 3, March 2001 (2001-03-01), pages 231 - 2
M PRENTKI; CJ NOLAN: "Islet beta-cell failure in type 2 diabetes", J. CLIN. INVESTIG., vol. 116, no. 7, 2006, pages 1802 - 1812
MAUGERI N. ET AL., SRP ARH CELOK LEK., vol. 138, no. 1, January 2010 (2010-01-01), pages 50 - 2
MCCONLOGUE ET AL.: "Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP Transgenic Mice", J BIOL CHEM., vol. 282, no. 36, 7 September 2007 (2007-09-07), pages 26326
MERTEN M. ET AL., Z KARDIOL., vol. 93, no. 11, November 2004 (2004-11-01), pages 855 - 63
NARENDER ET AL., TETRAHEDRON LETTERS, vol. 48, 2007, pages 6124 - 6128
P AKPINAR; S KUWAJIMA; J KR3TZFELDT; M STOFFEL: "Tmem27: A cleaved and shed plasma membrane protein that stimulates pancreatic ? cell proliferation", CELL METAB., vol. 2, 2005, pages 385 - 397
P KUHN; E MARJAUX; A IMHOF; B DE STROOPER ET AL.: "Regulated intramembrane proteolysis of the interleukin-1 receptor II by alpha-, beta-, and gamma-secretase", J. BIOL. CHEM., vol. 282, no. 16, 2007, pages 11982 - 11995
P ZIMMET; KGMM ALBERTI; J SHAW: "Global and societal implications of the diabetes epidemic", NATURE, vol. 414, 2001, pages 782 - 787
R.L.WALSKY; R.S.OBACH, DRUG METABOLISM AND DISPOSITION, vol. 32, 2004, pages 647 - 660
ROBERDS ET AL.: "BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics", HUM MOL GENET., vol. 10, no. 12, 1 June 2001 (2001-06-01), pages 1317 - 24
S WILD; G ROGLIC; A GREEN; R.SICREE; H KING: "Global prevalence of diabetes", DIABETES CARE, vol. 27, no. 5, 2004, pages 1047 - 1053
S.FOWLER; H.ZHANG, THE AAPS JOURNAL, vol. 10, no. 2, 2008, pages 410 - 424
SELKOE: "Cell biology of the amyloid beta-protein precursor and the mechanism of Alzheimer's disease", ANNU REV CELL BIOL., vol. 10, 1994, pages 373 - 403
SUGIMOTO I. ET AL., J BIOL CHEM., vol. 282, no. 48, 30 November 2007 (2007-11-30), pages 34896 - 903
T.P. TANG; J.A. ELLMAN, J. ORG. CHEM., vol. 64, 1999, pages 12
TALANTOV D. ET AL., CLIN CANCER RES., vol. 11, no. 20, 15 October 2005 (2005-10-15), pages 7234 - 42
TOEGEL S. ET AL., OSTEOARTHRITIS CARTILAGE, vol. 18, no. 2, February 2010 (2010-02-01), pages 240 - 8
VASSAR ET AL.: "Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE", SCIENCE, vol. 286, no. 5440, 22 October 1999 (1999-10-22), pages 735
VATTEMI G. ET AL., LANCET, vol. 358, no. 9297, 8 December 2001 (2001-12-08), pages 1962 - 4
WOODARD-GRICE A.V. ET AL., J BIOL CHEM., vol. 283, no. 39, 26 September 2008 (2008-09-26), pages 26364 - 73

Cited By (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546380B2 (en) 2005-10-25 2013-10-01 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives
US8173642B2 (en) 2005-10-25 2012-05-08 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives
US8815851B2 (en) 2005-10-25 2014-08-26 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives
US8633188B2 (en) 2005-10-25 2014-01-21 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives
US9029358B2 (en) 2005-10-25 2015-05-12 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives
US8884062B2 (en) 2007-04-24 2014-11-11 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives substituted with a cyclic group
US8895548B2 (en) 2007-04-24 2014-11-25 Shionogi & Co., Ltd. Pharmaceutical composition for treating alzheimer's disease
US8168630B2 (en) 2007-04-24 2012-05-01 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives substituted with a cyclic group
US8653067B2 (en) 2007-04-24 2014-02-18 Shionogi & Co., Ltd. Pharmaceutical composition for treating Alzheimer's disease
US9273053B2 (en) 2008-06-13 2016-03-01 Shionogi & Co., Ltd. Sulfur-containing heterocyclic derivative having Beta secretase inhibitory activity
US8637504B2 (en) 2008-06-13 2014-01-28 Shionogi & Co., Ltd. Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity
US9650371B2 (en) 2008-06-13 2017-05-16 Shionogi & Co., Ltd. Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity
US8703785B2 (en) 2008-10-22 2014-04-22 Shionogi & Co., Ltd. 2-aminopyrimidin-4-one and 2-aminopyridine derivatives both having BACE1-inhibiting activity
US8846658B2 (en) 2009-07-24 2014-09-30 Novartis Ag Oxazine derivatives and their use in the treatment of neurological disorders
US8207164B2 (en) 2009-07-24 2012-06-26 Novartis Ag Oxazine derivatives and their use in the treatment of neurological disorders
US9475785B2 (en) 2009-10-08 2016-10-25 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as BACE inhibitors, compositions and their use
US9687494B2 (en) 2009-10-08 2017-06-27 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
US8557826B2 (en) 2009-10-08 2013-10-15 Merck Sharp & Dohme Corp. Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions, and their use
US8563543B2 (en) 2009-10-08 2013-10-22 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
US8569310B2 (en) 2009-10-08 2013-10-29 Merck Sharp & Dohme Corp. Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions and their use
US8729071B2 (en) 2009-10-08 2014-05-20 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as BACE inhibitors, compositions and their use
US9428475B2 (en) 2009-10-08 2016-08-30 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
US8940748B2 (en) 2009-10-08 2015-01-27 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
US9029362B2 (en) 2009-10-08 2015-05-12 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as brace inhibitors, compositions, and their use
EP2511268B2 (en) † 2009-12-11 2021-02-17 Shionogi & Co., Ltd. Oxazine derivative
US9290466B2 (en) 2009-12-11 2016-03-22 Shionogi & Co., Ltd. Oxazine derivatives
US8999980B2 (en) 2009-12-11 2015-04-07 Shionogi & Co., Ltd. Oxazine derivatives
US9656974B2 (en) 2009-12-11 2017-05-23 Shionogi & Co., Ltd. Oxazine derivatives
US9828350B2 (en) 2010-06-09 2017-11-28 Janssen Pharmaceutica Nv 5,6-dihydro-2H-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (BACE)
US9018219B2 (en) 2010-10-29 2015-04-28 Shionogi & Co., Ltd. Fused aminodihydropyrimidine derivative
US8927721B2 (en) 2010-10-29 2015-01-06 Shionogi & Co., Ltd. Naphthyridine derivative
WO2012071279A1 (en) 2010-11-23 2012-05-31 Amgen Inc. Spiro-amino-imidazolone and spiro-amino-dihydro-pyrimidinone compounds as beta-secretase modulators and methods of use
US9840507B2 (en) 2010-12-22 2017-12-12 Janssen Pharmaceutica, Nv 5,6-dihydro-imidazo[1,2-a]pyrazin-8-ylamine derivatives useful as inhibitors of beta-secretase (BACE)
US8524897B2 (en) 2011-01-12 2013-09-03 Novartis Ag Crystalline oxazine derivative
US8637508B2 (en) 2011-01-13 2014-01-28 Novartis Ag Heterocyclic derivatives and their use in the treatment of neurological disorders
US10683287B2 (en) 2011-01-13 2020-06-16 Novartis Ag Heterocyclic derivatives and their use in the treatment of neurological disorders
US9550758B2 (en) 2011-01-13 2017-01-24 Novartis Ag Heterocyclic derivatives and their use in the treatment of neurological disorders
US10301296B2 (en) 2011-01-13 2019-05-28 Novartis Ag Heterocyclic derivatives and their use in the treatment of neurological disorders
US8865712B2 (en) 2011-01-13 2014-10-21 Novartis Ag Heterocyclic derivatives and their use in the treatment of neurological disorders
US10035794B2 (en) 2011-01-13 2018-07-31 Novartis Ag Heterocyclic derivatives and their use in the treatment of neurological disorders
WO2012107371A1 (en) 2011-02-08 2012-08-16 F. Hoffmann-La Roche Ag N-[3-(5-amino-3,3a,7,7a-tetrahydro-1h-2,4-dioxa-6-aza-inden-7-yl)-phenyl]-amides as bace1 and/or bace2 inhibitors
JP2014508751A (ja) * 2011-02-18 2014-04-10 エフ．ホフマン−ラ ロシュ アーゲー Ｂａｃｅ１及び／又はｂａｃｅ２阻害剤としての１，４−オキサゼピン類
US9845326B2 (en) 2011-03-09 2017-12-19 Janssen Pharmaceutica Nv Substituted 3,4-dihydropyrrolo[1,2-A]pyrazines as beta-secretase (BACE) inhibitors
US9145426B2 (en) 2011-04-07 2015-09-29 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
US9221839B2 (en) 2011-04-07 2015-12-29 Merck Sharp & Dohme Corp. C5-C6 oxacyclic-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
US9115098B2 (en) 2011-04-11 2015-08-25 Hoffman-La Roche Inc. 1,3-oxazines as BACE1 and/or BACE2 inhibitors
JP2014510769A (ja) * 2011-04-11 2014-05-01 エフ．ホフマン−ラ ロシュ アーゲー Ｂａｃｅ１及び／又はｂａｃｅ２阻害剤としての１，３−オキサジン
US9499502B2 (en) 2011-04-13 2016-11-22 Merck Sharp & Dohme Corp. 5-substituted iminothiazines and their mono- and dioxides as BACE inhibitors, compositions, and their use
WO2012147763A1 (ja) 2011-04-26 2012-11-01 塩野義製薬株式会社 オキサジン誘導体およびそれを含有するｂａｃｅ１阻害剤
CN103608345A (zh) * 2011-04-26 2014-02-26 盐野义制药株式会社 噁嗪衍生物和含有该噁嗪衍生物的bace1抑制剂
US8883779B2 (en) 2011-04-26 2014-11-11 Shinogi & Co., Ltd. Oxazine derivatives and a pharmaceutical composition for inhibiting BACE1 containing them
WO2012156284A1 (en) * 2011-05-16 2012-11-22 F. Hoffmann-La Roche Ag 1,3-oxazines as bace1 and/or bace2 inhibitors
CN103534243A (zh) * 2011-05-16 2014-01-22 霍夫曼-拉罗奇有限公司 作为bace1和/或bace2抑制剂的1,3-噁嗪类
US8785436B2 (en) 2011-05-16 2014-07-22 Hoffmann-La Roche Inc. 1,3-oxazines as BACE 1 and/or BACE2 inhibitors
JP2014515382A (ja) * 2011-05-27 2014-06-30 エフ．ホフマン−ラ ロシュ アーゲー Ｂａｃｅ１及び／又はｂａｃｅ２阻害剤としてのスピロ−［１，３］−オキサジン及びスピロ−［１，４］−オキサゼピン誘導体
JP2014516063A (ja) * 2011-06-07 2014-07-07 エフ．ホフマン−ラ ロシュ アーゲー Ｂａｃｅ１及び／又はｂａｃｅ２阻害剤としてのハロゲン−アルキル−１，３オキサジン
WO2012168164A1 (en) * 2011-06-07 2012-12-13 F. Hoffmann-La Roche Ag Halogen-alkyl-1,3 oxazines as bace1 and/or bace2 inhibitors
US8987255B2 (en) 2011-06-07 2015-03-24 Hoffmann-La Roche Inc. Halogen-alkyl-1,3 oxazines as BACE1 and/or BACE2 inhibitors
WO2012168175A1 (en) * 2011-06-07 2012-12-13 F. Hoffmann-La Roche Ag [1,3]oxazines
CN103608344A (zh) * 2011-06-07 2014-02-26 霍夫曼-拉罗奇有限公司 [1，3]噁嗪类
JP2014518895A (ja) * 2011-06-07 2014-08-07 エフ．ホフマン−ラ ロシュ アーゲー ［１，３］オキサジン
CN103608344B (zh) * 2011-06-07 2016-11-23 霍夫曼-拉罗奇有限公司 [1,3]噁嗪类
EA023261B1 (ru) * 2011-06-07 2016-05-31 Ф.Хоффманн-Ля Рош Аг Галоген-алкил-1,3-оксазины в качестве ингибиторов bace1 и(или) bace2
US9181236B2 (en) 2011-08-22 2015-11-10 Merck Sharp & Dohme Corp. 2-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use
US9163011B2 (en) 2011-08-25 2015-10-20 Novartis Ag Oxazine derivatives and their use in the treatment of disease
KR20140054313A (ko) * 2011-08-25 2014-05-08 노파르티스 아게 2-아미노-4-(피리딘-2-일)-5,6-디히드로-4h-1,3-옥사진 유도체 및 bace-1 및/또는 bace-2 억제제로서의 그의 용도
CN103906748A (zh) * 2011-08-25 2014-07-02 诺华股份有限公司 2-氨基-4-(吡啶-2-基)-5,6-二氢-4h-1,3-*嗪衍生物及其作为bace-1和/或bace-2抑制剂的用途
EA024580B1 (ru) * 2011-08-25 2016-09-30 Новартис Аг Производные 2-амино-4-(пиридин-2-ил)-5,6-дигидро-4h-1,3-оксазинов и их использование в качестве ингибиторов bace-1 и/или bace-2
EP3023423A1 (en) 2011-08-25 2016-05-25 Novartis AG 2 -amino-4 - (pyridin- 2 -yl) - 5, 6 -dihydro-4h- 1, 3 -oxazine derivatives and their use as bace-1 and/or bace - 2 inhibitors
AU2012298177B2 (en) * 2011-08-25 2015-10-29 Novartis Ag 2 -amino-4 - (pyridin- 2 -yl) - 5, 6 -dihydro-4h- 1, 3 -oxazine derivatives and their use as BACE-1 and/or BACE - 2 inhibitors
CN103906748B (zh) * 2011-08-25 2017-06-16 诺华股份有限公司 2‑氨基‑4‑(吡啶‑2‑基)‑5，6‑二氢‑4h‑1，3‑*嗪衍生物及其作为bace‑1和/或bace‑2抑制剂的用途
WO2013027188A1 (en) 2011-08-25 2013-02-28 Novartis Ag 2 -amino-4 - (pyridin- 2 -yl) - 5, 6 -dihydro-4h- 1, 3 -oxazine derivatives and their use as bace-1 and/or bace - 2 inhibitors
KR101601571B1 (ko) * 2011-08-25 2016-03-08 노파르티스 아게 2-아미노-4-(피리딘-2-일)-5,6-디히드로-4h-1,3-옥사진 유도체 및 bace-1 및/또는 bace-2 억제제로서의 그의 용도
WO2013041499A1 (en) * 2011-09-21 2013-03-28 F. Hoffmann-La Roche Ag N-(3-(2-amino-6,6-difluoro-4,4a,5,6,7,7a-hexahydro-cyclopenta[e][1,3]oxazin-4-yl)-phenyl)-amides as bace1 inhibitors
JP2014526534A (ja) * 2011-09-21 2014-10-06 エフ．ホフマン−ラ ロシュ アーゲー ＢＡＣＥ１阻害剤としてのＮ−（３−（２−アミノ−６，６−ジフルオロ−４，４ａ，５，６，７，７ａ−ヘキサヒドロ−シクロペンタ［ｅ］［１，３］オキサジン−４−イル）−フェニル）−アミド
US8476264B2 (en) 2011-09-21 2013-07-02 Hoffmann-La Roche Inc. N-(3-(2-amino-6,6-difluoro-4,4A,5,6,7,7A-hexahydro-cyclopenta[E][1,3]oxazin-4-yl)-phenylamides as BACE1 inhibitors
WO2013110622A1 (en) 2012-01-26 2013-08-01 F. Hoffmann-La Roche Ag Fluoromethyl-5,6-dihydro-4h-[1,3]oxazines
KR101669349B1 (ko) * 2012-01-26 2016-10-25 에프. 호프만-라 로슈 아게 플루오로메틸-5,6-다이하이드로-4h-[1,3]옥사진
CN104066727A (zh) * 2012-01-26 2014-09-24 霍夫曼-拉罗奇有限公司 氟甲基-5,6-二氢-4h-[1,3]噁嗪类
CN104066727B (zh) * 2012-01-26 2019-04-26 霍夫曼-拉罗奇有限公司 氟甲基-5,6-二氢-4h-[1,3]噁嗪类
EA027059B1 (ru) * 2012-01-26 2017-06-30 Ф.Хоффманн-Ля Рош Аг Фторметил-5,6-дигидро-4н-[1,3]оксазины
JP2015504906A (ja) * 2012-01-26 2015-02-16 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ フルオロメチル−５，６−ジヒドロ−４ｈ−［１，３］オキサジン
AU2013211646B2 (en) * 2012-01-26 2017-09-14 F. Hoffmann-La Roche Ag Fluoromethyl-5,6-dihydro-4h-[1,3]oxazines
US8338413B1 (en) 2012-03-07 2012-12-25 Novartis Ag Oxazine derivatives and their use in the treatment of neurological disorders
WO2013142613A1 (en) 2012-03-20 2013-09-26 Elan Pharmaceuticals, Inc. Spirocyclic dihydro-thiazine and dihydro-oxazine bace inhibitors, and compositions and uses thereof
WO2013174781A1 (en) 2012-05-24 2013-11-28 F. Hoffmann-La Roche Ag 5-amino[1,4]thiazines as bace 1 inhibitors
EA026004B1 (ru) * 2012-05-24 2017-02-28 Ф. Хоффманн-Ля Рош Аг 5-АМИНО[1,4]ТИАЗИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ β-СЕКРЕТАЗЫ 1
CN104470915A (zh) * 2012-06-26 2015-03-25 霍夫曼-拉罗奇有限公司 作为bace1抑制剂的二氟-六氢-环戊二烯并噁嗪基类和二氟-六氢-苯并噁嗪基类
WO2014001228A1 (en) * 2012-06-26 2014-01-03 F. Hoffmann-La Roche Ag Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors
EA025273B1 (ru) * 2012-06-26 2016-12-30 Ф. Хоффманн-Ля Рош Аг Дифторгексагидроциклопентаоксазинилы и дифторгексагидробензоксазинилы в качестве ингибиторов бета-секретазы 1
WO2014056816A1 (en) 2012-10-10 2014-04-17 F. Hoffmann-La Roche Ag COMBINATION OF AN Aβ ANTIBODY AND A BACE INHIBITOR
US9556135B2 (en) 2012-10-12 2017-01-31 Amgen, Inc. Amino-dihydrothiazine and amino-dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use
WO2014059185A1 (en) 2012-10-12 2014-04-17 Amgen Inc. Amino - dihydrothiazine and amino - dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use
JP2016501827A (ja) * 2012-10-24 2016-01-21 塩野義製薬株式会社 Ｂａｃｅ１阻害作用を有するジヒドロオキサジンまたはオキサゼピン誘導体
US9540359B2 (en) 2012-10-24 2017-01-10 Shionogi & Co., Ltd. Dihydrooxazine or oxazepine derivatives having BACE1 inhibitory activity
WO2014065434A1 (en) * 2012-10-24 2014-05-01 Shionogi & Co., Ltd. Dihydrooxazine or oxazepine derivatives having bace1 inhibitory activity
US9758513B2 (en) 2012-10-24 2017-09-12 Shionogi & Co., Ltd. Dihydrooxazine or oxazepine derivatives having BACE1 inhibitory activity
WO2014120658A1 (en) 2013-01-29 2014-08-07 Amgen Inc. Fused multicyclic 3-amino-5,6-dihydro-2h-1,4-thiazine derivatives and their use as beta-secretase inhibitors
WO2014134341A1 (en) 2013-03-01 2014-09-04 Amgen Inc. Perfluorinated 5,6-dihydro-4h-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use
JP2016511258A (ja) * 2013-03-01 2016-04-14 アムジエン・インコーポレーテツド ベータ−セクレターゼ阻害剤としてのパーフルオロ化５，６−ジヒドロ−４ｈ−１，３−オキサジン−２−アミン化合物および使用方法
US9296734B2 (en) 2013-03-01 2016-03-29 Amgen Inc. Perfluorinated 5,6-dihydro-4H-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use
US9611261B2 (en) 2013-03-08 2017-04-04 Amgen Inc. Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use
WO2014138484A1 (en) 2013-03-08 2014-09-12 Amgen Inc. Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use
US9085576B2 (en) 2013-03-08 2015-07-21 Amgen Inc. Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use
US11447478B2 (en) 2013-04-11 2022-09-20 Hoffmann-La Roche Inc. BACE1 inhibitors
WO2014173917A1 (en) * 2013-04-26 2014-10-30 F. Hoffmann-La Roche Ag Synthesis of bace1 inhibitors
US9751886B2 (en) 2013-06-12 2017-09-05 Janssen Pharmaceutica Nv 4-amino-6-phenyl-6,7-dihydro[1,2,3]triazolo[1,5-A]pyrazine derivatives as inhibitors of beta-secretase (BACE)
US9834559B2 (en) 2013-06-12 2017-12-05 Janssen Pharmaceutica Nv 4-Amino-6-phenyl-5,6-dihydroimidazo[1,5-a]pyrazin-3(2H)-one derivatives as inhibitors of beta-secretase (BACE)
WO2015017407A1 (en) 2013-07-30 2015-02-05 Amgen Inc. Bridged bicyclic amino thiazine dioxide compounds as inhibitors of beta- secretase
WO2015156421A1 (en) 2014-04-11 2015-10-15 Shionogi & Co., Ltd. Dihydrothiazine and dihydrooxazine derivatives having bace1 inhibitory activity
KR20160141849A (ko) 2014-04-11 2016-12-09 시오노기세이야쿠가부시키가이샤 Bace1 저해 작용을 갖는 디하이드로티아진 및 디하이드로옥사진 유도체
US9550762B2 (en) 2014-08-08 2017-01-24 Amgen, Inc. Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use
US10106524B2 (en) 2014-12-18 2018-10-23 Janssen Pharmaceutica Nv 2,3,4,5-tetrahydropyridin-6-amine and 3,4-dihydro-2H-pyrrol-5-amine compound inhibitors of beta-secretase
WO2016150785A1 (en) 2015-03-20 2016-09-29 F. Hoffmann-La Roche Ag Bace1 inhibitors
US10246429B2 (en) 2015-08-06 2019-04-02 Amgen Inc. Vinyl fluoride cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use
WO2017061534A1 (en) 2015-10-08 2017-04-13 Shionogi & Co., Ltd. Dihydrothiazine derivatives
WO2018112086A1 (en) 2016-12-15 2018-06-21 Amgen Inc. Cyclopropyl fused thiazine derivatives as beta-secretase inhibitors and methods of use
WO2018112081A1 (en) 2016-12-15 2018-06-21 Amgen Inc. Oxazine derivatives as beta-secretase inhibitors and methods of use
US10889579B2 (en) 2016-12-15 2021-01-12 Amgen Inc. Thiazine derivatives as β-secretase inhibitors and methods of use
US10889581B2 (en) 2016-12-15 2021-01-12 Amgen Inc. Cyclopropyl fused thiazine derivatives as beta-secretase inhibitors and methods of use
WO2018112084A1 (en) 2016-12-15 2018-06-21 Amgen Inc. Bicyclic thiazine and oxazine derivatives as beta-secretase inhibitors and methods of use
US10947223B2 (en) 2016-12-15 2021-03-16 Amgen Inc. Substituted oxazines as beta-secretase inhibitors
US11021493B2 (en) 2016-12-15 2021-06-01 Amgen Inc. 1,4-thiazine dioxide and 1,2,4-thiadiazine dioxide derivatives as beta-secretase inhibitors and methods of use
WO2018112083A1 (en) 2016-12-15 2018-06-21 Amgen Inc. Thiazine derivatives as beta-secretase inhibitors and methods of use
US11548903B2 (en) 2016-12-15 2023-01-10 Amgen Inc. Bicyclic thiazine and oxazine derivatives as beta-secretase inhibitors and methods of use
US11629154B2 (en) 2018-04-27 2023-04-18 Shionogi & Co., Ltd. Tetrahydropyranooxazine derivatives having selective BACE1 inhibitory activity

Also Published As

Publication number Publication date
SG181610A1 (en) 2012-07-30
BR112012013175A2 (pt) 2019-09-24
NZ599008A (en) 2013-08-30
IL219107A (en) 2015-10-29
JP5584778B2 (ja) 2014-09-03
CL2012001464A1 (es) 2014-03-07
CN102712609A (zh) 2012-10-03
UA103272C2 (uk) 2013-09-25
AR079327A1 (es) 2012-01-18
US20110144097A1 (en) 2011-06-16
PE20121500A1 (es) 2012-11-05
ECSP12011961A (es) 2012-07-31
KR20120104598A (ko) 2012-09-21
CA2776727A1 (en) 2011-06-16
JP2013513563A (ja) 2013-04-22
MA34779B1 (fr) 2014-01-02
US8389513B2 (en) 2013-03-05
MX2012006493A (es) 2012-07-03
CR20120262A (es) 2012-07-27
RU2515221C2 (ru) 2014-05-10
TWI487704B (zh) 2015-06-11
MY169962A (en) 2019-06-19
IL219107A0 (en) 2012-06-28
EP2509965A1 (en) 2012-10-17
KR101506773B1 (ko) 2015-03-27
IN2012DN03043A (uk) 2015-07-31
CO6541656A2 (es) 2012-10-16
TW201124408A (en) 2011-07-16
RU2012126989A (ru) 2014-01-20
AU2010330031A1 (en) 2012-06-07
AU2010330031B2 (en) 2013-06-20
CA2776727C (en) 2016-05-31

Similar Documents

Publication Publication Date Title
CA2776727C (en) 2-amino-5,5-difluoro-5,6-dihydro-4h-oxazines as bace 1 and/or bace 2 inhibitors
US9115098B2 (en) 1,3-oxazines as BACE1 and/or BACE2 inhibitors
US8399459B2 (en) 1,4 oxazines as BACE1 and/or BACE2 inhibitors
US8987255B2 (en) Halogen-alkyl-1,3 oxazines as BACE1 and/or BACE2 inhibitors
US8404680B2 (en) N-[3-(5-amino-3,3a,7,7a-tetrahydro-1H-2,4-dioxa-6-aza-inden-7-yl)-phenyl]-amides as BACE1 and/or BACE2 inhibitors
CA2856892C (en) Fluoromethyl-5,6-dihydro-4h-[1,3]oxazines
EP2665713A1 (en) 1,4 oxazines as bace1 and/or bace2 inhibitors
AU2013202820A1 (en) 2-Amino-5, 5-difluoro-5, 6-dihydro-4H-oxazines as BACE 1 and/or BACE 2 inhibitors
NZ614545B2 (en) 1,3 oxazines as bace1 and/or bace2 inhibitors

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080056151.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10785437

Country of ref document: EP

Kind code of ref document: A1

REEP Request for entry into the european phase

Ref document number: 2010785437

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2010785437

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12012500619

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 12054495

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 2776727

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 219107

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 3043/DELNP/2012

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2010330031

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: CR2012-000262

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: MX/A/2012/006493

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2010330031

Country of ref document: AU

Date of ref document: 20101206

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 000803-2012

Country of ref document: PE

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2012542481

Country of ref document: JP

Ref document number: 1201002739

Country of ref document: TH

WWE Wipo information: entry into national phase

Ref document number: A201208098

Country of ref document: UA

WWE Wipo information: entry into national phase

Ref document number: 12113850

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 20127017919

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2012126989

Country of ref document: RU

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012013175

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112012013175

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20120531